{"gene":"PRMT1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1998,"finding":"Recombinant HRMT1L2 (PRMT1) protein exhibits arginine methyltransferase activity in vitro and complements a yeast HMT1 mutant strain in vivo, establishing it as a functional human arginine methyltransferase.","method":"In vitro methyltransferase assay with recombinant protein; yeast complementation assay","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay plus in vivo complementation, two orthogonal methods in a single study","pmids":["9545638"],"is_preprint":false},{"year":1999,"finding":"PRMT1 binds specifically to the intracytoplasmic domain of the IFNAR-1 chain of the type I interferon receptor (not IFNAR-2 or PRMT2), and reduced PRMT1 expression diminishes the antiviral and antiproliferative effects of IFN-β.","method":"Co-immunoprecipitation; antisense-mediated knockdown with VSV replication assay and cell growth inhibition assay","journal":"Journal of interferon & cytokine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding demonstrated, functional knockdown with specific phenotypic readout, single lab","pmids":["10090404"],"is_preprint":false},{"year":2008,"finding":"PRMT1 and CARM1 cooperate as coactivators of STAT5-dependent transcription; cytokine stimulation induces a physical association between STAT5 and both PRMTs, and both enzymes are recruited to the CITED2 gene promoter as direct co-activators.","method":"siRNA double knockdown; cDNA microarray; ChIP; reporter gene assay; co-immunoprecipitation","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP, co-IP, reporter assay, microarray), single lab","pmids":["18413343"],"is_preprint":false},{"year":2008,"finding":"PRMT1 physically interacts with orphan receptor TR3 and stabilizes TR3 protein (independent of methyltransferase activity), enhancing TR3 transcriptional activity; reciprocally, TR3 binding to the catalytic domain of PRMT1 inhibits PRMT1 methyltransferase activity, altering methylation of PRMT1 substrates STAT3 and Sam68.","method":"Co-immunoprecipitation; methyltransferase activity assay; luciferase reporter assay; TR3-knockdown cells and TR3-knockout mice","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction and enzymatic activity measured, in vivo validation in knockout mice, single lab","pmids":["19095693"],"is_preprint":false},{"year":2011,"finding":"PRMT1 and PRMT2 directly interact, and this interaction stimulates PRMT1 methyltransferase activity (increased Vmax and altered Km); complex formation requires full-length active PRMT1 and the SH3 domain of PRMT2 contributes to a methylation-dependent interaction.","method":"Co-immunoprecipitation; bimolecular fluorescence complementation; in vitro methyltransferase assays; active-site mutagenesis and domain deletions","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted interaction and enzymatic assay with mutagenesis, multiple orthogonal methods, single lab","pmids":["21851090"],"is_preprint":false},{"year":2015,"finding":"PRMT1 methylates RBM15 at R578, promoting its ubiquitylation by E3 ligase CNOT4 and subsequent proteasomal degradation; reduced RBM15 protein impairs recruitment of splicing factor SF3B1 to intronic regions of megakaryopoiesis genes (GATA1, RUNX1, TAL1, c-MPL), thereby regulating alternative splicing.","method":"Co-immunoprecipitation; in vitro methylation assay; ubiquitylation assay; RNA-IP; rescue experiments with RBM15 overexpression","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation, ubiquitylation assay, multiple binding assays, functional rescue, replicated across cell lines","pmids":["26575292"],"is_preprint":false},{"year":2015,"finding":"PRMT1 methylates EGFR at R198 and R200 of the extracellular domain, enhancing EGF binding, receptor dimerization, and downstream signaling; methylation-defective EGFR mutants reduce tumor growth and restore sensitivity to cetuximab.","method":"In vitro methylation assay; site-directed mutagenesis; binding assay; mouse orthotopic colorectal cancer xenograft model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, mutagenesis, in vivo xenograft validation, multiple orthogonal methods","pmids":["26571401"],"is_preprint":false},{"year":2015,"finding":"PRMT1 enzymatic activity is inhibited under oxidative conditions via cysteine oxidation to sulfenic acid (-SOH); this inhibition is reversible by reduction, representing a redox-sensitive regulatory mechanism distinct from changes in protein expression.","method":"In vitro methyltransferase activity assay; hydrogen peroxide dose-response; cysteine oxidation detection","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mechanistic detail, single lab, single method type","pmids":["25911106"],"is_preprint":false},{"year":2015,"finding":"PRMT1 and PRMT8 act as selective modulators of retinoic acid receptor (RAR/RXR) transcriptional activity in neuronal differentiation; loss of either reduces nuclear arginine methylation and dysregulates neuronal gene expression, affecting neuronal cell fate.","method":"siRNA knockdown; RNA-seq; neuronal differentiation model of murine ESCs; electrophysiology","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with transcriptomic and functional readout, multiple methods, single lab","pmids":["25388207"],"is_preprint":false},{"year":2017,"finding":"PRMT1 methylates CDK4, preventing formation of the CDK4-Cyclin-D3 complex and thereby inducing cell cycle arrest in pre-B cells; BTG2 acts as an adaptor facilitating PRMT1 methylation of CDK4.","method":"Co-immunoprecipitation; in vitro methylation assay; cell cycle analysis; in vitro and in vivo proliferation assays with BCR-ABL1-transformed pre-B cells","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation of CDK4 confirmed, complex formation shown, in vivo functional validation, single lab with multiple orthogonal methods","pmids":["28628091"],"is_preprint":false},{"year":2017,"finding":"PRMT1 methylates the transcriptional co-activator Eya1, and loss of PRMT1 in muscle stem cells prevents Eya1 methylation, reducing Eya1 recruitment to the MyoD promoter and suppressing Eya1/Six1-dependent MyoD expression, thereby impairing muscle stem cell differentiation.","method":"In vitro methylation assay; conditional Pax7CreERT2-driven Prmt1 knockout; ChIP; co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation assay, conditional KO model, ChIP demonstrating mechanism, single lab with multiple orthogonal methods","pmids":["27849571"],"is_preprint":false},{"year":2017,"finding":"PRMT1 depletion impairs arginine methylation of the translation initiation complex, disrupting its assembly and inhibiting cap-dependent translation; this represents a critical vulnerability in p53-deficient cancer cells.","method":"shRNA screen; mechanistic proteomics; translation initiation complex assembly assay; in vitro and in vivo tumor models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic depletion with proteomic pathway analysis and functional translation assay, single lab","pmids":["28655788"],"is_preprint":false},{"year":2018,"finding":"PRMT1 methylates CaMKII at R9 and R275, inhibiting CaMKII activity; cardiac-specific PRMT1 deletion leads to CaMKII hyperactivation, dilated cardiomyopathy and heart failure, which is rescued by pharmacological CaMKII inhibition.","method":"Cardiac-specific Prmt1 knockout mice; in vitro methylation assay; co-immunoprecipitation; CaMKII activity assay; pharmacological rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation with site identification, conditional KO with clear phenotype, pharmacological rescue, multiple orthogonal methods","pmids":["30504773"],"is_preprint":false},{"year":2018,"finding":"PRMT1 methylates SMAD7 at the TGF-β receptor complex, promoting SMAD7 dissociation from receptors and enabling TGF-β-induced SMAD3 activation; this mechanism is required for TGF-β-induced EMT and epithelial stem-cell generation.","method":"In vitro methylation assay; co-immunoprecipitation; siRNA knockdown; EMT and stem-cell functional assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation demonstrated, functional epistasis shown, single lab","pmids":["29907569"],"is_preprint":false},{"year":2018,"finding":"GFI1 interacts with PRMT1 and its substrates MRE11 and 53BP1, enabling PRMT1 to bind and methylate these DNA repair proteins; GFI1 loss abolishes PRMT1-dependent methylation of MRE11 and 53BP1 and causes defective DNA damage response.","method":"Co-immunoprecipitation; in vitro methylation assay; GFI1 knockout T cells; ionizing radiation sensitivity assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate methylation demonstrated in vitro and in vivo, adaptor function shown by co-IP and KO, single lab","pmids":["29651020"],"is_preprint":false},{"year":2018,"finding":"RANKL treatment increases PRMT1 expression and promotes its nuclear localization in bone marrow-derived macrophages via JNK-dependent signaling; PRMT1 directly interacts with NF-κB and regulates its transcriptional activity during osteoclastogenesis.","method":"siRNA knockdown; PRMT1 haploinsufficient cells; co-immunoprecipitation; TRAP staining; in vivo OVX mouse model","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with defined cellular phenotype, co-IP for interaction, in vivo validation, single lab","pmids":["30154485"],"is_preprint":false},{"year":2019,"finding":"PRMT1 methylates FLT3-ITD at R972/R973; this methylation promotes AML maintenance and cross-talks with FLT3 phosphorylation at Y969; importantly, FLT3 methylation persists following kinase inhibitor treatment, indicating independence from kinase activity.","method":"Co-immunoprecipitation; in vitro methylation assay; PRMT1-knockout mouse; patient-derived xenograft and murine AML models; combined inhibitor treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation with site identification, PRMT1 KO mouse, PDX in vivo model, multiple orthogonal methods","pmids":["31217189"],"is_preprint":false},{"year":2019,"finding":"PRMT1 asymmetrically dimethylates UBAP2L at its RGG motif; increased arginine methylation of UBAP2L blocks its interactions with stress granule (SG) components (mRNPs, RBPs, ribosomal subunits), preventing SG assembly, while decreased methylation promotes SG assembly.","method":"In vitro methylation assay; stress granule assembly/disassembly assays; immunofluorescence; co-immunoprecipitation","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation shown, SG functional consequence demonstrated, single lab with multiple methods","pmids":["31114027"],"is_preprint":false},{"year":2019,"finding":"PRMT1 methylates SRSF1, and this methylation is required for SRSF1 binding with RNA; in the absence of PRMT1, SRSF1 methylation and SRSF1-dependent splicing functions are impaired.","method":"In vitro methylation assay; RNA-binding assay; siRNA knockdown; splicing reporter assay","journal":"Journal of hematology & oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro methylation mentioned but mechanistic detail is limited in the abstract; primarily correlation data","pmids":["22839530"],"is_preprint":false},{"year":2019,"finding":"Loss of PRMT1 sensitizes cells to PRMT5 inhibition; MTAP-deleted cells with attenuated PRMT5-MEP50 signaling are more sensitive to PRMT1 inhibition, demonstrating functional redundancy between PRMT1 (asymmetric methylation) and PRMT5 (symmetric methylation) pathways.","method":"CRISPR/Cas9 genetic screen; pharmacological inhibitor combination; cell viability assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen with pharmacological validation, pathway epistasis established, single lab","pmids":["30916320"],"is_preprint":false},{"year":2019,"finding":"PRMT1 is constitutively bound to IGF-1R and becomes activated upon IGF-1 stimulation; activated PRMT1 methylates ERα at R260, triggering formation of the mERα/Src/PI3K complex and non-genomic IGF-1 signaling in breast cancer cells.","method":"Co-immunoprecipitation; in vitro methylation assay; PRMT1 inhibition/knockdown; signaling pathway analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding and activation shown by co-IP, methylation confirmed in vitro and in cells, single lab","pmids":["30692633"],"is_preprint":false},{"year":2019,"finding":"PRMT1 methylates ATF4 at R239, stabilizing ATF4 protein; ATF4 methylation-deficient mutant R239K exacerbates ER stress and apoptosis in cardiomyocytes; PRMT1 null hearts show exacerbated ER stress.","method":"In vitro methylation assay; site-directed mutagenesis; PRMT1 conditional knockout heart; ER stress markers","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation with mutagenesis, conditional KO model, mechanistic protein stability assay, single lab multiple orthogonal methods","pmids":["31787756"],"is_preprint":false},{"year":2019,"finding":"PRMT1 is required for maintaining β-cell identity; PRMT1-dependent H4R3me2a increases chromatin accessibility at CTCF and β-cell transcription factor binding sites, as revealed by ChIP-seq and ATAC-seq in β-cell-specific Prmt1 knockout mice.","method":"β-cell-specific Prmt1 knockout; ChIP-seq; ATAC-seq; gene expression profiling","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1 / Strong — conditional KO with genome-wide chromatin accessibility profiling, mechanistic link established between H4R3me2a and chromatin opening, multiple orthogonal methods","pmids":["31848151"],"is_preprint":false},{"year":2019,"finding":"Deep proteomic methylation profiling identified 18 high-confidence PRMT1 substrates; PRMT1 knockdown caused significant loss of asymmetric dimethylarginine (ADMA) marks on 78 proteins enriched for mRNA metabolic processes; some sites (e.g., HNRNPA1 R206) switch from ADMA to SDMA upon PRMT1 knockdown, revealing dynamic interplay between methyltransferases.","method":"Immunoaffinity purification and strong cation exchange enrichment; mass spectrometry; PRMT1 knockdown","journal":"Molecular & cellular proteomics : MCP","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic proteomic approach with two orthogonal enrichment methods, PRMT1 KD validated, single lab","pmids":["31451547"],"is_preprint":false},{"year":2019,"finding":"Alcohol induces PRMT1 dephosphorylation at S297; phosphorylation at S297 is necessary for PRMT1-dependent protein arginine methylation and regulation of pro-inflammatory and pro-apoptotic gene expression, while oxidative stress response gene regulation is phosphorylation-independent.","method":"AAV-Cre-mediated hepatocyte-specific PRMT1 knockout; phosphorylation mimic/null mutants (S297A, S297D); gene expression analysis; in vitro methyltransferase assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with phospho-mutant rescue, in vivo mouse model, single lab","pmids":["31235809"],"is_preprint":false},{"year":2020,"finding":"PRMT1 is recruited to chromatin by DNA-PK in response to cisplatin; DNA-PK phosphorylates PRMT1, directing its enzymatic activity toward H4R3 (producing H4R3me2a) at pro-inflammatory gene promoters, thereby sustaining the senescence-associated secretory phenotype (SASP).","method":"Mass spectrometry-based proteomics; co-immunoprecipitation; ChIP; H4R3me2a chromatin profiling; clonogenic assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for DNA-PK/PRMT1 interaction, ChIP for chromatin recruitment, functional SASP readout, single lab","pmids":["31995759"],"is_preprint":false},{"year":2020,"finding":"PRMT1 regulates Mdm4 pre-mRNA splicing; loss of PRMT1 shifts Mdm4 splicing toward a shorter isoform, leading to p53 accumulation, enhanced Slug degradation, and blockade of EMT in epicardial cells.","method":"Epicardial-specific Prmt1 deletion; scRNA-seq; splicing analysis; p53 pathway readouts; in vivo epicardial invasion assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined splicing and signaling mechanism, in vivo validation, single lab","pmids":["32521264"],"is_preprint":false},{"year":2020,"finding":"PRMT1 methylates EZH2 at R342 (meR342-EZH2); this methylation inhibits CDK1-mediated phosphorylation at EZH2 T345 and T487, thereby attenuating TRAF6-mediated ubiquitylation and increasing EZH2 protein stability.","method":"In vitro methylation assay; co-immunoprecipitation; phosphorylation and ubiquitylation assays; site-directed mutagenesis","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic cross-talk with phosphorylation and ubiquitylation established, multiple orthogonal methods, single lab","pmids":["32895488"],"is_preprint":false},{"year":2020,"finding":"PRMT1 methylates SCYL1 at the γ2-COP binding site; this methylation is required for SCYL1 interaction with γ2-COP and COPI vesicle function; PRMT1 colocalizes with SCYL1 in the Golgi fraction, and inhibition of PRMT1 causes abnormal Golgi morphology and impairs axon and dendrite outgrowth.","method":"In vitro methylation assay; co-immunoprecipitation; subcellular fractionation; siRNA knockdown; neurite outgrowth assay; rescue with methylation-site SCYL1 mutant","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation, Golgi colocalization by fractionation, binding assay, siRNA KD with mutant rescue, multiple methods, single lab","pmids":["32583741"],"is_preprint":false},{"year":2020,"finding":"PRMT1 suppresses doxorubicin-induced cardiotoxicity; doxorubicin induces PRMT1 translocation to the endoplasmic reticulum, where PRMT1 methylates ATF4 to suppress the PERK/ATF4/CHOP proapoptotic ER stress pathway.","method":"PRMT1 overexpression/depletion in H9c2 cardiomyocytes; subcellular fractionation/translocation assay; ER stress marker analysis; in vitro methylation assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ER translocation shown by fractionation, ATF4 methylation linked to ER stress suppression, single lab","pmids":["35863589"],"is_preprint":false},{"year":2021,"finding":"PRMT1 methylates NONO at R251; this asymmetric dimethylation promotes colorectal cancer cell proliferation, migration, and invasion; NONO R251K mutant cells show reduced malignant phenotype.","method":"Mass spectrometry; in vitro methylation assay; NONO R251K mutant cell lines; PRMT1 knockdown and pharmacological inhibition; xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation with MS validation, site mutagenesis with functional phenotype, in vivo xenograft, single lab","pmids":["33420374"],"is_preprint":false},{"year":2021,"finding":"PRMT1-mediated H4R3me2a directly recruits SMARCA4 (an ATPase subunit of the SWI/SNF complex) to chromatin; SMARCA4 acts as a novel effector of H4R3me2a and cooperates with PRMT1 to activate EGFR and TNS4 transcription in colorectal cancer cells.","method":"Co-immunoprecipitation; ChIP; ChIP-seq; cell proliferation/migration assays; in vivo CRC mouse model","journal":"Genome medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ChIP-seq demonstrate direct H4R3me2a–SMARCA4 recruitment, in vivo model, single lab","pmids":["33853662"],"is_preprint":false},{"year":2021,"finding":"PRMT1 inhibition in PDAC impairs RNA metabolism including splicing, alternative polyadenylation, and transcription termination, causing downregulation of DNA damage response pathways and promoting genomic instability.","method":"RNAi in vivo functional genomics; proteomic and transcriptomic analyses; pharmacological PRMT1 inhibition; patient-derived PDAC models","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide transcriptomic/proteomic mechanistic analysis, in vivo RNAi screen validation, single lab","pmids":["34330913"],"is_preprint":false},{"year":2021,"finding":"PRMT1 methylates EZH2 at R342, promoting PRC2 complex assembly by facilitating EZH2 interaction with SUZ12 and preventing AMPKα1-mediated phosphorylation at T311; this results in enhanced H3K27me3 at P16 and P21 promoters and promotes breast cancer cell proliferation.","method":"In vitro methylation assay; co-immunoprecipitation; ChIP; site-directed mutagenesis; in vitro and in vivo proliferation assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation, mechanistic cross-talk with phosphorylation and PRC2 assembly shown, ChIP validation, single lab","pmids":["34775498"],"is_preprint":false},{"year":2021,"finding":"PRMT1 promotes TBK1 activation by directly interacting with TBK1 and catalyzing asymmetric methylation at R54, R134, and R228; this methylation enhances TBK1 oligomerization and subsequent TBK1 phosphorylation, promoting type I interferon production; myeloid-specific Prmt1 KO mice are more susceptible to viral infection.","method":"Co-immunoprecipitation; in vitro methylation assay; site-directed mutagenesis; myeloid-specific Prmt1 knockout mice; viral infection model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation with site identification, conditional KO mouse, in vivo viral infection phenotype, multiple orthogonal methods","pmids":["34551290"],"is_preprint":false},{"year":2021,"finding":"Naturally occurring cancer-associated mutations in the PRMT1 dimerization arm (W215L, Y220N, M224V) disrupt oligomer formation and substantially impair SAM binding and methyltransferase activity, demonstrating that dimerization through the dimerization arm is required for PRMT1 catalytic function.","method":"Site-directed mutagenesis; analytical ultracentrifugation; native PAGE; in vitro methyltransferase activity assay; molecular dynamics simulations","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with biophysical and activity assays, mechanistic characterization of dimerization-activity link, single lab with multiple orthogonal methods","pmids":["34688662"],"is_preprint":false},{"year":2022,"finding":"Wnt activation upregulates PRMT1 expression in CD8+ T cells; PRMT1-mediated H4R3me2a deposition at the IL-2 promoter is required for Wnt-induced T cell polyfunctionality and IL-2 production; PRMT1 inhibition abrogates the polyfunctionality effect.","method":"Chromatin immunoprecipitation; PRMT1 inhibition; gene expression profiling; cytokine production assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates mechanistic link between H4R3me2a and IL-2 promoter, inhibitor validates PRMT1 requirement, single lab","pmids":["35040433"],"is_preprint":false},{"year":2022,"finding":"PRMT1 promotes adipogenesis by catalyzing H4R3me2a to upregulate PPARγ expression; PRMT1 also stabilizes C/EBPβ protein by decreasing the E3 ubiquitin ligase Smurf2 levels, and interacts with C/EBPβ to promote its phosphorylation.","method":"Gain and loss of function (siRNA/overexpression); H4R3me2a ChIP; co-immunoprecipitation; ubiquitylation assay; adipogenesis assay in 3T3-L1 and C3H10T1/2 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — histone modification shown by ChIP, protein stability mechanism by ubiquitylation assay, multiple substrates, single lab","pmids":["35921899"],"is_preprint":false},{"year":2022,"finding":"PRMT1 methylates SRSF1, which is critical for SRSF1 phosphorylation, SRSF1 binding to RNA, and exon inclusion; PRMT1 overexpression in breast tumors is associated with increased SRSF1 arginine methylation and aberrant exon inclusion patterns that drive cancer cell growth.","method":"PRMT1 methylome profiling; in vitro methylation assay; RNA binding assay; splicing reporter; PRMT1 inhibitor iPRMT1; breast cancer cell growth assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation, RNA binding assay, splicing functional readout, pharmacological and genetic validation, single lab with multiple methods","pmids":["37938975"],"is_preprint":false},{"year":2023,"finding":"PRMT1 methylates cGAS at conserved R133, preventing cGAS dimerization and suppressing cGAS/STING innate immune signaling in cancer cells; genetic or pharmacological PRMT1 ablation activates cGAS/STING-dependent type I and II interferon responses and increases tumor-infiltrating lymphocytes.","method":"In vitro methylation assay; site-directed mutagenesis; cGAS dimerization assay; cGAS/STING pathway reporter; in vivo tumor model with anti-PD-1 combination","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation at defined site, mechanistic dimerization assay, in vivo immunotherapy combination, multiple orthogonal methods","pmids":["37193698"],"is_preprint":false},{"year":2023,"finding":"PRMT1 methylates PHGDH at R236, activating PHGDH catalytic activity and promoting serine biosynthesis, oxidative stress resistance, and HCC tumor growth; blocking PHGDH methylation with a TAT-tagged peptide inhibits serine synthesis and restrains HCC growth in PDX and xenograft models.","method":"In vitro methylation assay; mass spectrometry; PHGDH activity assay; PDX and xenograft mouse models; metabolomics","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation with site identification, enzyme activity assay, in vivo PDX model, mechanistic peptide rescue, multiple orthogonal methods","pmids":["36823188"],"is_preprint":false},{"year":2023,"finding":"CDK5 phosphorylates PRMT1 at S307, promoting its translocation from nucleus to cytoplasm and lysosome; cytoplasmic PRMT1 then methylates WDR24 (a GATOR2 complex component) to activate mTORC1 signaling in response to amino acids.","method":"Co-immunoprecipitation; subcellular fractionation; in vitro methylation assay; mTORC1 signaling assay; xenograft tumor model","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation-driven translocation shown by fractionation, substrate methylation confirmed, pathway activation measured, single lab","pmids":["36995937"],"is_preprint":false},{"year":2023,"finding":"PRMT1 methylates WTAP (a key m6A methyltransferase complex component); WTAP methylation promotes m6A modification of NDUFS6 mRNA, activating oxidative phosphorylation in multiple myeloma cells.","method":"Co-immunoprecipitation; in vitro methylation assay; m6A sequencing; PRMT1 knockdown; OXPHOS functional assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation of WTAP, m6A downstream effect shown, single lab","pmids":["37558663"],"is_preprint":false},{"year":2023,"finding":"PRMT1 methylates RIP3 at R486 (R479 in mouse), inhibiting RIP3 interaction with RIP1 and suppression of the RIP1-RIP3 necrosome complex, thereby blocking RIP3 phosphorylation and necroptosis activation; methylation-deficient RIP3 promotes necroptosis and tumor immune escape.","method":"In vitro methylation assay; co-immunoprecipitation; RIP3 phosphorylation assay; MDSC infiltration assay; clinical sample analysis with RIP3 di-methylation-specific antibody","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic interaction disruption shown, functional necroptosis assay, single lab","pmids":["37005412"],"is_preprint":false},{"year":2023,"finding":"PRMT1 methylates BRD4 at R179/R181/R183 (antagonized by JMJD6 demethylase); PRMT1-mediated BRD4 methylation promotes BRD4 phosphorylation and ovarian cancer invasion; BRD4 R179/181/183K mutant cells show reduced metastasis.","method":"In vitro methylation assay; site-directed mutagenesis; co-immunoprecipitation; JMJD6 demethylation assay; invasion and migration assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation with site identification, writer/eraser pair demonstrated, functional mutagenesis, single lab","pmids":["37737256"],"is_preprint":false},{"year":2023,"finding":"PRMT1-dependent H4R3me2a at the Dnmt1 enhancer region maintains DNMT1 expression; PRMT1 deficiency reduces DNMT1 levels, activating endogenous retroviral element (ERV) transcription and double-stranded RNA production, which stimulates interferon signaling and anti-tumor CD8+ T cell responses.","method":"ChIP; PRMT1 knockout; DNMT1 expression analysis; ERV transcription assay; in vivo tumor model with anti-PD-1","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP links H4R3me2a to DNMT1 enhancer, mechanistic pathway validated in vivo, single lab","pmids":["37991725"],"is_preprint":false},{"year":2023,"finding":"PRMT1 promotes c-Fos protein stability by methylating c-Fos at R287, protecting it from autophagic degradation; PRMT1-mediated methylation enhances AP-1 transcriptional activity and promotes gastric tumorigenesis.","method":"Co-immunoprecipitation; in vitro methylation assay; autophagy flux assay; PRMT1 knockdown; c-Fos stability assay","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation, protein stability mechanism via autophagy shown, single lab","pmids":["37564212"],"is_preprint":false},{"year":2023,"finding":"PRMT1 asymmetrically methylates METTL14 at two major arginine residues in its C-terminal RGG repeats; this methylation is recognized by reader protein SPF30 and is essential for METTL14 function in catalyzing m6A modification.","method":"In vitro methylation assay; co-immunoprecipitation; m6A modification assay; PRMT1 inhibitor MS023; cell proliferation assay","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation, reader identification, downstream m6A effect shown, single lab","pmids":["37269817"],"is_preprint":false},{"year":2024,"finding":"FBXO7 binds PRMT1 and promotes its K37 ubiquitination and proteasomal degradation, thereby suppressing PHGDH arginine methylation/activation and serine synthesis in HCC; FBXO7 is downregulated in human HCC and inversely correlates with PRMT1 protein levels.","method":"Co-immunoprecipitation; ubiquitylation assay; PHGDH activity assay; in vitro and in vivo HCC models","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitylation site identified, functional consequence on downstream methylation shown, in vivo validation, single lab","pmids":["38839752"],"is_preprint":false},{"year":2024,"finding":"PRMT1 methylates PHGDH at R54 and R20 (and also PFKFB3 and PKM2), stabilizing PHGDH by suppressing polyubiquitination and activating it by stabilizing 3-phosphoglycerate binding; this drives serine synthesis pathway flux, increases citrate/palmitate via fatty acid synthase, and promotes chemoresistance in TNBC.","method":"In vitro methylation assay; 13C metabolic flux analysis; site mutagenesis; protein stability assay; FASN inhibition; clinical specimen IHC with imaging mass spectrometry","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation at defined sites, metabolic flux analysis, mutagenesis, clinical tissue validation, multiple orthogonal methods","pmids":["38383964"],"is_preprint":false},{"year":2024,"finding":"PRMT1 methylates PGK1 at R206; this meR206-PGK1 enhances phosphorylation at S203, inhibiting mitochondrial function and promoting aerobic glycolysis in colorectal cancer cells.","method":"In vitro methylation assay; phosphorylation assay; mitochondrial function assay; glycolysis assay; clinical tissue correlation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic cross-talk with phosphorylation shown, functional metabolic readout, single lab","pmids":["38402202"],"is_preprint":false},{"year":2024,"finding":"PRMT1 methylates DDX3 to enhance its protein stability and prevent proteasomal degradation; stabilized DDX3 translocates to mitochondria and facilitates PINK1 translation in response to mitochondrial stress, coordinating mitophagy and mitochondrial biogenesis to support breast cancer metastasis.","method":"In vitro methylation assay; protein stability assay; mitochondrial fractionation; PINK1 translation assay; in vivo metastasis model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation, mitochondrial translocation shown by fractionation, translation assay, in vivo metastasis, single lab","pmids":["39042374"],"is_preprint":false},{"year":2024,"finding":"p53 activation under glucose-deficient conditions suppresses USP7 and promotes polyubiquitin-dependent degradation of PRMT1; melatonin-mediated reduction of glucose uptake downregulates PRMT1 via this p53-USP7 axis in p53 wild-type NSCLC.","method":"PRMT1 degradation assay; USP7 inhibitor; p53 activation experiments; cell viability assay","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanism inferred from inhibitor studies and expression analysis, limited direct biochemical demonstration in abstract","pmids":["39009589"],"is_preprint":false},{"year":2024,"finding":"PRMT1 suppresses IFNγ-induced MHC-I expression by limiting STAT1 expression and activation; PRMT1 knockout or pharmacological inhibition (GSK3368715) elevates STAT1 and MHC-I, enhancing CD8+ T cell-mediated tumor killing and potentiating anti-PD-1 immunotherapy.","method":"CRISPR-Cas9 epigenetic screen; PRMT1 KO; pharmacological inhibition; STAT1 expression and phosphorylation analysis; CD8+ T cell cytotoxicity assay; in vivo anti-PD-1 combination","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen with KO validation, STAT1/MHC-I mechanistic link, in vivo immunotherapy confirmation, single lab","pmids":["38401121"],"is_preprint":false},{"year":2024,"finding":"PRMT1 methylates PARP1; this methylation promotes PARP1-dependent DNA damage repair and activates NF-κB (P65) signaling, enhancing cancer cell stemness and immune suppression, thereby driving chemoresistance and lung metastasis in TNBC.","method":"Mass spectrometry; co-immunoprecipitation; NF-κB signaling assay; in vitro and in vivo metastasis and chemoresistance assays","journal":"Research (Washington, D.C.)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — interaction validated by MS and co-IP, downstream pathway effects shown, but detailed methylation site and direct mechanistic validation limited in abstract","pmids":["40927753"],"is_preprint":false},{"year":2025,"finding":"PRMT1 methylates TDP-43 at R293; R293 methylation permits TDP-43 liquid-liquid phase separation (LLPS) and reduces pathological TDP-43 aggregation; S292 phosphorylation (by p38α) reduces R293 methylation, establishing reciprocal cross-talk between p38α-mediated phosphorylation and PRMT1-mediated methylation in controlling TDP-43 proteinopathy.","method":"In vitro methylation assay; site-directed mutagenesis; LLPS assay; TDP-43 aggregation assay; ALS patient-derived motor neurons; p38α inhibition","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation at defined site, LLPS assay, cross-talk with phosphorylation demonstrated by mutagenesis, ALS patient cell validation, multiple orthogonal methods","pmids":["39817908"],"is_preprint":false},{"year":2020,"finding":"PRMT1 is required for PRMT1-dependent expression of FEN1 (a DNA repair endonuclease) via post-translational modification; elevated PRMT1 maintains high FEN1 levels, contributing to DNA repair capacity and drug resistance in lung cancer cells.","method":"PRMT1 knockdown; post-translational modification analysis; FEN1 expression and activity assay; drug resistance assay","journal":"DNA repair","confidence":"Low","confidence_rationale":"Tier 3 / Weak — relationship between PRMT1 and FEN1 shown but mechanism of PTM-driven FEN1 upregulation not fully detailed in abstract","pmids":["32861926"],"is_preprint":false},{"year":2022,"finding":"EphA2 directly interacts with PRMT1 (by co-IP and GST pulldown), increases PRMT1 expression and activity; PRMT1 in turn methylates SOX2, promoting stemness and chemoresistance in small-cell lung cancer.","method":"Co-immunoprecipitation; GST pulldown; PRMT1 activity assay; in vitro methylation of SOX2; PDX model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal pulldown for interaction, in vitro SOX2 methylation, in vivo PDX validation, single lab","pmids":["36377249"],"is_preprint":false},{"year":2022,"finding":"PRMT1 promotes hepatic fatty acid oxidation to prevent diet-induced steatosis through methyltransferase activity-dependent induction of PGC-1α mRNA expression via HNF-4α recruitment to the PGC-1α promoter; methyltransferase-defective PRMT1G80R fails to alleviate steatosis.","method":"AAV-mediated hepatic PRMT1 overexpression/knockdown; PRMT1G80R catalytic mutant; ChIP (HNF-4α at PGC-1α promoter); fatty acid oxidation assay; diet-induced obese mouse model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic mutant distinguishes methyltransferase-dependent effects, ChIP mechanistic evidence, in vivo mouse model, single lab","pmids":["35401831"],"is_preprint":false},{"year":2021,"finding":"TIPE1 binds to the catalytic domain of PRMT1 and inhibits PRMT1-mediated asymmetric dimethylation of STAT3 at R688; loss of this methylation decreases STAT3 transactivation and suppresses osteosarcoma malignancy.","method":"Co-immunoprecipitation; in vitro methylation assay; STAT3 transactivation assay; TIPE1 overexpression/knockdown; in vivo osteosarcoma model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic domain interaction shown, in vitro methylation of STAT3, in vivo model, single lab","pmids":["36151091"],"is_preprint":false},{"year":2020,"finding":"Crystal structures of CARM1 and PRMT1 bound to bisubstrate inhibitors reveal that a residue differing between CARM1 (Asn-265) and PRMT1 (Tyr-160) affects the side chain conformation of the catalytically important neighboring glutamate; mutagenesis confirms this residue contributes to differential inhibitor binding.","method":"X-ray crystallography; isothermal titration calorimetry; methyltransferase activity assay; site-directed mutagenesis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of PRMT1 active site with inhibitors, ITC binding measurement, mutagenesis validation, single lab with multiple orthogonal methods","pmids":["32011657"],"is_preprint":false},{"year":2020,"finding":"H4 Ser-1 phosphorylation inhibits PRMT1-catalyzed asymmetric dimethylation of H4R3; H4K5 acetylation reduces PRMT1 catalytic efficiency while enhancing PRMT5-mediated symmetric dimethylation at the same site, revealing that local histone modifications regulate PRMT1 substrate selectivity.","method":"In vitro methyltransferase assay using synthetic modified H4 peptides; kinetic analysis","journal":"Epigenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with modified substrates, kinetic characterization, single lab","pmids":["33380261"],"is_preprint":false},{"year":2024,"finding":"LPCAT2 regulates acetylation of PRMT1 at K145, arresting PRMT1 in the cytoplasm of CRC cells; this prevents PRMT1-mediated nuclear activation of the SLC7A11 promoter, thereby reducing SLC7A11 expression, increasing lipid peroxidation, and inducing ferroptosis.","method":"scRNA-seq; co-immunoprecipitation; PRMT1 acetylation assay; SLC7A11 promoter luciferase assay; LPCAT2 knockout mice; ferroptosis assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — K145 acetylation–nuclear exclusion mechanism shown, promoter assay, in vivo KO model, single lab","pmids":["38605214"],"is_preprint":false},{"year":2024,"finding":"In gemcitabine-treated PDAC cells, PRMT1 translocates to the nucleus where its methyltransferase activity limits assembly of chromatin-bound MAFF/BACH1 transcriptional complexes; disrupting this axis delays acquired gemcitabine resistance.","method":"Genetic and pharmacological PRMT1 inhibition; Cut&Tag chromatin profiling (H3K27Ac, MAFF, BACH1); MAFF genetic silencing; gemcitabine resistance assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear translocation shown, chromatin occupancy profiling mechanistic, in vivo PDX validation, single lab","pmids":["38691454"],"is_preprint":false}],"current_model":"PRMT1 is the predominant type I protein arginine methyltransferase in mammals that catalyzes monomethylation and asymmetric dimethylation of arginine residues in histones (notably H4R3me2a) and a broad range of non-histone substrates—including RBM15, EGFR, EZH2, FLT3, CaMKII, TBK1, cGAS, PHGDH, PGK1, SMAD7, CDK4, Eya1, SCYL1, UBAP2L, ATF4, SRSF1, TDP-43, and many others—thereby regulating transcription, RNA splicing, signal transduction, DNA damage response, innate immunity, metabolic reprogramming, and cell fate determination; its enzymatic activity depends on homodimerization through a dimerization arm, is stimulated by interaction with PRMT2 and inhibited by oxidation of active-site cysteines or binding of TR3 to its catalytic domain, and is controlled by upstream post-translational modifications including CDK5-mediated phosphorylation at S307 (promoting cytoplasmic/lysosomal translocation) and p53/USP7-mediated ubiquitin-dependent degradation, with FBXO7 targeting K37 for proteasomal degradation."},"narrative":{"mechanistic_narrative":"PRMT1 is the predominant mammalian type I protein arginine methyltransferase, catalyzing arginine monomethylation and asymmetric dimethylation of histone and non-histone substrates to regulate transcription, RNA processing, signal transduction, DNA damage response, innate immunity, and metabolic reprogramming [PMID:9545638, PMID:31451547]. Its catalytic activity requires homodimerization through a dimerization arm—cancer-associated mutations in this arm (W215L, Y220N, M224V) abolish oligomer formation and impair SAM binding and turnover [PMID:34688662]—and is allosterically stimulated by direct interaction with PRMT2 [PMID:21851090] while being repressed by reversible oxidation of active-site cysteines to sulfenic acid [PMID:25911106] and by TR3 binding to the catalytic domain [PMID:19095693]. On chromatin, PRMT1 deposits H4R3me2a to open chromatin and drive lineage- and stimulus-specific transcriptional programs, recruiting the SWI/SNF ATPase SMARCA4 as an effector [PMID:33853662], maintaining DNMT1 enhancer activity to silence endogenous retroviruses [PMID:37991725], and sustaining β-cell identity, adipogenesis, and inducible cytokine genes [PMID:31848151, PMID:35921899, PMID:35040433]. Beyond histones, PRMT1 methylates a large repertoire of substrates—including EGFR, FLT3-ITD, CaMKII, SMAD7, EZH2, CDK4, cGAS, TBK1, PHGDH, PGK1, ATF4, SRSF1, and TDP-43—frequently engaging in cross-talk with phosphorylation, ubiquitylation, and other modifications to control protein stability, activity, complex assembly, and localization [PMID:26571401, PMID:31217189, PMID:30504773, PMID:32895488, PMID:37193698, PMID:34551290, PMID:36823188, PMID:39817908]. Many substrates are accessed through adaptor proteins (BTG2 for CDK4, GFI1 for MRE11/53BP1) [PMID:28628091, PMID:29651020], and substrate selectivity at H4R3 is tuned by neighbouring histone marks such as H4S1 phosphorylation and H4K5 acetylation [PMID:33380261]. PRMT1 itself is positioned by upstream signaling: CDK5 phosphorylation at S307 drives nucleocytoplasmic/lysosomal translocation toward mTORC1 activation [PMID:36995937], K145 acetylation arrests it in the cytoplasm [PMID:38605214], and its abundance is set by FBXO7-mediated K37 ubiquitylation and p53/USP7-dependent degradation [PMID:38839752, PMID:39009589]. Through these activities PRMT1 functions as a context-dependent driver of cancer cell proliferation, metabolic flux, chemoresistance, and immune evasion, and conversely protects cardiomyocytes from CaMKII hyperactivation and ER stress [PMID:38383964, PMID:38401121, PMID:30504773, PMID:31787756].","teleology":[{"year":1998,"claim":"Established the founding identity of the human protein as a bona fide arginine methyltransferase rather than an uncharacterized ORF.","evidence":"In vitro methyltransferase assay with recombinant protein plus complementation of a yeast HMT1 mutant","pmids":["9545638"],"confidence":"High","gaps":["Did not identify physiological substrates","No structure or catalytic mechanism defined","Symmetric vs asymmetric product specificity not resolved"]},{"year":1999,"claim":"Linked PRMT1 to a defined receptor pathway by showing it binds the IFNAR-1 cytoplasmic tail and supports type I interferon responses.","evidence":"Co-IP with IFNAR chains plus antisense knockdown with VSV and growth assays","pmids":["10090404"],"confidence":"Medium","gaps":["No methylation substrate at the receptor identified","Binding specificity not structurally mapped"]},{"year":2008,"claim":"Defined PRMT1 as a transcriptional coactivator recruited to target promoters and as a target of allosteric inhibition by an interacting orphan receptor.","evidence":"ChIP, reporter assays, and co-IP for STAT5/CITED2 coactivation; reciprocal TR3 interaction with catalytic-domain inhibition and substrate methylation changes","pmids":["18413343","19095693"],"confidence":"Medium","gaps":["Direct histone marks at coactivated promoters not measured in STAT5 work","TR3 inhibitory binding site not mapped at residue level"]},{"year":2011,"claim":"Showed PRMT1 activity is positively regulated by protein-protein interaction, establishing PRMT2 as an allosteric stimulator.","evidence":"Co-IP, BiFC, in vitro kinetics with domain deletions and active-site mutagenesis","pmids":["21851090"],"confidence":"High","gaps":["Physiological context of PRMT1-PRMT2 modulation not defined","No structure of the stimulated complex"]},{"year":2015,"claim":"Expanded PRMT1 into non-histone substrate biology, demonstrating methylation that controls substrate stability, receptor signaling, and splicing-factor function.","evidence":"In vitro methylation, mutagenesis, ubiquitylation/RNA-IP/rescue, and xenografts for RBM15 (R578) and EGFR (R198/R200)","pmids":["26575292","26571401"],"confidence":"High","gaps":["Generality of methylation-coupled degradation across substrates unknown","Extracellular EGFR methylation topology not structurally explained"]},{"year":2015,"claim":"Identified redox sensing as a post-translational control of PRMT1, distinct from expression-level regulation.","evidence":"In vitro activity assay with H2O2 dose-response and reversible cysteine oxidation detection","pmids":["25911106"],"confidence":"Medium","gaps":["Oxidized cysteine residues not definitively mapped to active site","In vivo redox regulation not demonstrated"]},{"year":2017,"claim":"Demonstrated adaptor-dependent substrate selection and lineage-specific transcriptional control, with in vivo conditional-knockout validation.","evidence":"BTG2-facilitated CDK4 methylation with cell-cycle assays; conditional Prmt1 KO with ChIP linking Eya1 methylation to MyoD induction","pmids":["28628091","27849571"],"confidence":"High","gaps":["Methylated residues on CDK4 and Eya1 not fully mapped","How adaptors confer specificity mechanistically unresolved"]},{"year":2018,"claim":"Established PRMT1 as a regulator of signaling, DNA repair, and developmental transitions through substrate methylation and adaptor recruitment, with physiological consequences in heart.","evidence":"Cardiac KO with CaMKII methylation and pharmacological rescue; SMAD7 methylation in TGF-β/EMT; GFI1-dependent methylation of MRE11/53BP1","pmids":["30504773","29907569","29651020"],"confidence":"High","gaps":["MRE11/53BP1 methylation sites and DDR mechanism not fully defined","SMAD7 methylation site not pinpointed in this study"]},{"year":2019,"claim":"Defined PRMT1 as a global regulator of RNA metabolism and a context-specific cancer dependency, and quantified its methylproteome.","evidence":"Proteomic ADMA profiling (18 high-confidence substrates; ADMA-to-SDMA switching), translation-initiation and FLT3-ITD/AML KO models, CRISPR PRMT1/PRMT5 synthetic lethality","pmids":["31451547","28655788","31217189","30916320"],"confidence":"High","gaps":["Functional consequence of most ADMA sites untested","Mechanism of ADMA/SDMA scavenging interplay incomplete"]},{"year":2019,"claim":"Extended PRMT1 control to stress-granule dynamics, nuclear receptor non-genomic signaling, ER-stress protein stability, and chromatin accessibility for cell identity.","evidence":"UBAP2L RGG methylation/SG assays; IGF-1R-bound PRMT1 methylating ERα R260; ATF4 R239 methylation with cardiac KO; β-cell KO with ChIP-seq/ATAC-seq linking H4R3me2a to open chromatin","pmids":["31114027","30692633","31787756","31848151"],"confidence":"High","gaps":["How a single enzyme balances nuclear vs cytoplasmic substrate pools not resolved here","Direct vs indirect chromatin opening by H4R3me2a not separable in KO"]},{"year":2020,"claim":"Resolved the structural basis of PRMT1 inhibitor selectivity and dimerization-dependent catalysis, and showed neighbouring histone marks tune substrate choice.","evidence":"Crystal structures/ITC of PRMT1 with bisubstrate inhibitors; dimerization-arm mutants with biophysics and activity; modified H4 peptide kinetics","pmids":["32011657","33380261"],"confidence":"High","gaps":["Full enzyme-substrate complex structures for non-histone substrates lacking","Dynamics of dimer assembly in cells not measured"]},{"year":2020,"claim":"Showed PRMT1 chromatin recruitment and translocation are signal-driven, coupling DNA damage and Golgi/secretory functions to its methyltransferase activity.","evidence":"DNA-PK-mediated recruitment/phosphorylation directing H4R3me2a at SASP genes; SCYL1 methylation with Golgi colocalization and neurite-outgrowth rescue; Mdm4 splicing control in epicardium","pmids":["31995759","32583741","32521264"],"confidence":"Medium","gaps":["PRMT1 phosphosite targeted by DNA-PK not identified","SCYL1 methylation site not fully defined"]},{"year":2021,"claim":"Consolidated PRMT1 as a hub coupling histone marks to effector recruitment and as a stabilizer/activator of chromatin and immune-signaling proteins.","evidence":"H4R3me2a-dependent SMARCA4 recruitment; EZH2 R342 methylation cross-talk stabilizing protein and promoting PRC2 assembly; TBK1 methylation (R54/R134/R228) with myeloid KO viral susceptibility; PDAC RNA-metabolism dependency","pmids":["33853662","32895488","34775498","34551290","34330913"],"confidence":"High","gaps":["How H4R3me2a is read by SMARCA4 structurally unknown","Substrate prioritization during infection not defined"]},{"year":2022,"claim":"Expanded PRMT1 into immune-cell programming, adipogenesis, hepatic metabolism, and additional substrate-stability/stemness axes.","evidence":"H4R3me2a at IL-2 promoter for CD8+ polyfunctionality; PPARγ/C/EBPβ control in adipogenesis; catalytic-mutant-validated PGC-1α/HNF-4α hepatic FAO; EphA2-PRMT1-SOX2 stemness","pmids":["35040433","35921899","35401831","36377249"],"confidence":"Medium","gaps":["Direct vs indirect targets in metabolic programs incompletely separated","SOX2 methylation site not mapped"]},{"year":2023,"claim":"Defined PRMT1 as a brake on innate-immune and necroptotic signaling and a driver of metabolic and m6A-related reprogramming, with translational implications for immunotherapy.","evidence":"cGAS R133 methylation blocking dimerization/STING; RIP3 R486 methylation suppressing necrosome; PHGDH R236 activation; WTAP and METTL14 methylation regulating m6A; DNMT1-enhancer H4R3me2a controlling ERV/IFN; BRD4, c-Fos, NONO methylation","pmids":["37193698","37005412","36823188","37558663","37269817","37991725","37737256","37564212","33420374"],"confidence":"High","gaps":["Selectivity that determines which substrate dominates in a given tumor context unresolved","Reader-mediated outputs (e.g., SPF30) functionally underexplored"]},{"year":2024,"claim":"Mapped upstream control of PRMT1 abundance and localization and detailed its role in metabolic flux, mitochondrial fate, and immune evasion.","evidence":"FBXO7 K37 ubiquitylation; CDK5-S307 phosphorylation driving translocation and WDR24/mTORC1 activation; K145 acetylation (LPCAT2) cytoplasmic arrest controlling SLC7A11/ferroptosis; PHGDH R54/R20, PGK1 R206, DDX3 methylation; STAT1/MHC-I suppression; nuclear MAFF/BACH1 restraint","pmids":["38839752","36995937","38605214","38383964","38402202","39042374","38401121","38691454"],"confidence":"High","gaps":["Integration of competing localization signals (phospho/acetyl) not unified mechanistically","Causal hierarchy among multiple metabolic substrates unclear"]},{"year":2025,"claim":"Connected PRMT1 to neurodegenerative proteostasis by showing methylation controls phase separation and aggregation of an ALS-relevant substrate.","evidence":"TDP-43 R293 in vitro methylation, LLPS and aggregation assays, p38α phospho cross-talk, ALS patient-derived motor neurons","pmids":["39817908"],"confidence":"High","gaps":["Therapeutic modulation of this axis in vivo untested","Stoichiometry of methylation vs phosphorylation in patient tissue unknown"]},{"year":null,"claim":"It remains unresolved how PRMT1 selects among its very large substrate repertoire in a given cell, and how its competing localization, modification, and degradation signals are integrated into context-specific outputs.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for substrate prioritization across nucleus, cytoplasm, Golgi, ER, and mitochondria","Quantitative occupancy and stoichiometry of most methylation sites in vivo unknown","Adaptor- vs intrinsic-specificity contributions not systematically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,6,9,12,22,34,40,49,55]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,6,9,12,27,34,39,40,43,55]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[22,25,31,61]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,3,22,31]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,4,7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15,22,25,41,62,63]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17,41,62]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[28]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[29]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[22,25,31]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,22,31,36,45]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[5,18,32,38,42,47]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,34,39,53]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,13,16,20,34]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[40,42,49,50,58]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[9,27,33]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[14,54]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22,31,45,61]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[21,43,62]}],"complexes":[],"partners":["PRMT2","TR3","EGFR","TBK1","EZH2","IGF1R","FLT3","GFI1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99873","full_name":"Protein arginine N-methyltransferase 1","aliases":["Histone-arginine N-methyltransferase PRMT1","Interferon receptor 1-bound protein 4"],"length_aa":371,"mass_kda":42.5,"function":"Arginine methyltransferase that methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues present in proteins such as ESR1, histone H2, H3 and H4, FMR1, ILF3, HNRNPA1, HNRNPD, NFATC2IP, SUPT5H, TAF15, EWS, HABP4, SERBP1, RBM15, FOXO1, CHTOP, MAP3K5/ASK1, MICU1 and NPRL2 (PubMed:10749851, PubMed:15741314, PubMed:16879614, PubMed:18951090, PubMed:22095282, PubMed:25284789, PubMed:26575292, PubMed:26876602, PubMed:27642082, PubMed:30765518, PubMed:31257072, PubMed:38006878). Constitutes the main enzyme that mediates monomethylation and asymmetric dimethylation of histone H4 'Arg-3' (H4R3me1 and H4R3me2a, respectively), a specific tag for epigenetic transcriptional activation. May be involved in the regulation of TAF15 transcriptional activity, act as an activator of estrogen receptor (ER)-mediated transactivation, play a key role in neurite outgrowth and act as a negative regulator of megakaryocytic differentiation, by modulating p38 MAPK pathway. Methylates RBM15, promoting ubiquitination and degradation of RBM15 (PubMed:26575292). Methylates MRE11 and TP53BP1, promoting the DNA damage response (PubMed:15741314, PubMed:16294045, PubMed:29651020). Methylates FOXO1 and retains it in the nucleus increasing its transcriptional activity (PubMed:18951090). Methylates CHTOP and this methylation is critical for its 5-hydroxymethylcytosine (5hmC)-binding activity (PubMed:25284789). Methylates MAP3K5/ASK1 at 'Arg-78' and 'Arg-80' which promotes association of MAP3K5 with thioredoxin and negatively regulates MAP3K5 association with TRAF2, inhibiting MAP3K5 stimulation and MAP3K5-induced activation of JNK (PubMed:22095282). Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner (PubMed:25284789). Plays a role in regulating alternative splicing in the heart (By similarity). Methylates NPRL2 at 'Arg-78' leading to inhibition of its GTPase activator activity and then the GATOR1 complex and consequently inducing timely mTORC1 activation under methionine-sufficient conditions (PubMed:38006878). Methylates the C-terminus of DSP, promoting its phosphorylation by GSK3B and subsequent recruitment to desmosome cell-cell junctions (PubMed:25733715)","subcellular_location":"Nucleus; Nucleus, nucleoplasm; Cytoplasm; Cytoplasm, cytosol; Lysosome membrane","url":"https://www.uniprot.org/uniprotkb/Q99873/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PRMT1","classification":"Common Essential","n_dependent_lines":1192,"n_total_lines":1208,"dependency_fraction":0.9867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"LSM14A","stoichiometry":4.0},{"gene":"ATG101","stoichiometry":0.2},{"gene":"ATG13","stoichiometry":0.2},{"gene":"ATG3","stoichiometry":0.2},{"gene":"ATG4B","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"DHX9","stoichiometry":0.2},{"gene":"EMC8","stoichiometry":0.2},{"gene":"EMC9","stoichiometry":0.2},{"gene":"ENY2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRMT1","total_profiled":1310},"omim":[{"mim_id":"620689","title":"LSM FAMILY, MEMBER 14B; LSM14B","url":"https://www.omim.org/entry/620689"},{"mim_id":"617369","title":"HYALURONAN-BINDING PROTEIN 4; HABP4","url":"https://www.omim.org/entry/617369"},{"mim_id":"614525","title":"NFATC2-INTERACTING PROTEIN; NFATC2IP","url":"https://www.omim.org/entry/614525"},{"mim_id":"614392","title":"TUDOR DOMAIN-CONTAINING PROTEIN 3; TDRD3","url":"https://www.omim.org/entry/614392"},{"mim_id":"614206","title":"CHROMATIN TARGET OF PRMT1; CHTOP","url":"https://www.omim.org/entry/614206"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRMT1"},"hgnc":{"alias_symbol":["HCP1","ANM1"],"prev_symbol":["HRMT1L2"]},"alphafold":{"accession":"Q99873","domains":[{"cath_id":"3.40.50.150","chopping":"49-162","consensus_level":"high","plddt":94.6932,"start":49,"end":162},{"cath_id":"2.70.160.11","chopping":"195-369","consensus_level":"high","plddt":97.2142,"start":195,"end":369}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99873","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99873-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99873-F1-predicted_aligned_error_v6.png","plddt_mean":88.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRMT1","jax_strain_url":"https://www.jax.org/strain/search?query=PRMT1"},"sequence":{"accession":"Q99873","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99873.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99873/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99873"}},"corpus_meta":[{"pmid":"26575292","id":"PMC_26575292","title":"Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26575292","citation_count":160,"is_preprint":false},{"pmid":"9545638","id":"PMC_9545638","title":"Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9545638","citation_count":152,"is_preprint":false},{"pmid":"32895488","id":"PMC_32895488","title":"Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/32895488","citation_count":144,"is_preprint":false},{"pmid":"26571401","id":"PMC_26571401","title":"PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26571401","citation_count":129,"is_preprint":false},{"pmid":"36823188","id":"PMC_36823188","title":"PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36823188","citation_count":116,"is_preprint":false},{"pmid":"19643181","id":"PMC_19643181","title":"The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation.","date":"2009","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/19643181","citation_count":114,"is_preprint":false},{"pmid":"33853662","id":"PMC_33853662","title":"PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling.","date":"2021","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33853662","citation_count":113,"is_preprint":false},{"pmid":"34833023","id":"PMC_34833023","title":"Structure, Activity, and Function of PRMT1.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34833023","citation_count":96,"is_preprint":false},{"pmid":"30916320","id":"PMC_30916320","title":"PRMT1 loss sensitizes cells to PRMT5 inhibition.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30916320","citation_count":80,"is_preprint":false},{"pmid":"31217189","id":"PMC_31217189","title":"PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31217189","citation_count":78,"is_preprint":false},{"pmid":"31114027","id":"PMC_31114027","title":"UBAP2L arginine methylation by PRMT1 modulates stress granule assembly.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31114027","citation_count":77,"is_preprint":false},{"pmid":"30504773","id":"PMC_30504773","title":"Cardiac specific PRMT1 ablation causes heart failure through CaMKII dysregulation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30504773","citation_count":73,"is_preprint":false},{"pmid":"37193698","id":"PMC_37193698","title":"PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37193698","citation_count":72,"is_preprint":false},{"pmid":"18413343","id":"PMC_18413343","title":"The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18413343","citation_count":68,"is_preprint":false},{"pmid":"29907569","id":"PMC_29907569","title":"Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29907569","citation_count":65,"is_preprint":false},{"pmid":"24211191","id":"PMC_24211191","title":"CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.","date":"2013","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/24211191","citation_count":64,"is_preprint":false},{"pmid":"38839752","id":"PMC_38839752","title":"FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38839752","citation_count":62,"is_preprint":false},{"pmid":"34330913","id":"PMC_34330913","title":"PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34330913","citation_count":57,"is_preprint":false},{"pmid":"33420374","id":"PMC_33420374","title":"PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33420374","citation_count":57,"is_preprint":false},{"pmid":"27849571","id":"PMC_27849571","title":"Arginine Methylation by PRMT1 Regulates Muscle Stem Cell Fate.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27849571","citation_count":55,"is_preprint":false},{"pmid":"32521264","id":"PMC_32521264","title":"PRMT1-p53 Pathway Controls Epicardial EMT and Invasion.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32521264","citation_count":54,"is_preprint":false},{"pmid":"22839530","id":"PMC_22839530","title":"Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia.","date":"2012","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22839530","citation_count":53,"is_preprint":false},{"pmid":"31995759","id":"PMC_31995759","title":"PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31995759","citation_count":53,"is_preprint":false},{"pmid":"34775498","id":"PMC_34775498","title":"PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34775498","citation_count":52,"is_preprint":false},{"pmid":"29651020","id":"PMC_29651020","title":"GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29651020","citation_count":52,"is_preprint":false},{"pmid":"33859753","id":"PMC_33859753","title":"PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33859753","citation_count":51,"is_preprint":false},{"pmid":"38402202","id":"PMC_38402202","title":"PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38402202","citation_count":49,"is_preprint":false},{"pmid":"19344311","id":"PMC_19344311","title":"Characterization of PRMT1 from Plasmodium falciparum.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19344311","citation_count":49,"is_preprint":false},{"pmid":"31451547","id":"PMC_31451547","title":"Deep Protein Methylation Profiling by Combined Chemical and Immunoaffinity Approaches Reveals Novel PRMT1 Targets.","date":"2019","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/31451547","citation_count":48,"is_preprint":false},{"pmid":"28628091","id":"PMC_28628091","title":"The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex.","date":"2017","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28628091","citation_count":46,"is_preprint":false},{"pmid":"25388207","id":"PMC_25388207","title":"PRMT1 and PRMT8 regulate retinoic acid-dependent neuronal differentiation with implications to neuropathology.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/25388207","citation_count":45,"is_preprint":false},{"pmid":"25911106","id":"PMC_25911106","title":"Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25911106","citation_count":44,"is_preprint":false},{"pmid":"38383964","id":"PMC_38383964","title":"PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38383964","citation_count":43,"is_preprint":false},{"pmid":"29026071","id":"PMC_29026071","title":"Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29026071","citation_count":43,"is_preprint":false},{"pmid":"30236171","id":"PMC_30236171","title":"PRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression.","date":"2018","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/30236171","citation_count":43,"is_preprint":false},{"pmid":"37558663","id":"PMC_37558663","title":"PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37558663","citation_count":42,"is_preprint":false},{"pmid":"37144835","id":"PMC_37144835","title":"PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia.","date":"2023","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/37144835","citation_count":42,"is_preprint":false},{"pmid":"21851090","id":"PMC_21851090","title":"A protein arginine N-methyltransferase 1 (PRMT1) and 2 heteromeric interaction increases PRMT1 enzymatic activity.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21851090","citation_count":42,"is_preprint":false},{"pmid":"34551290","id":"PMC_34551290","title":"The protein arginine methyltransferase PRMT1 promotes TBK1 activation through asymmetric arginine methylation.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34551290","citation_count":40,"is_preprint":false},{"pmid":"30692633","id":"PMC_30692633","title":"The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30692633","citation_count":40,"is_preprint":false},{"pmid":"10090404","id":"PMC_10090404","title":"Involvement of receptor-bound protein methyltransferase PRMT1 in antiviral and antiproliferative effects of type I interferons.","date":"1999","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/10090404","citation_count":40,"is_preprint":false},{"pmid":"19095693","id":"PMC_19095693","title":"A feedback regulatory loop between methyltransferase PRMT1 and orphan receptor TR3.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19095693","citation_count":38,"is_preprint":false},{"pmid":"28671608","id":"PMC_28671608","title":"Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28671608","citation_count":36,"is_preprint":false},{"pmid":"36922568","id":"PMC_36922568","title":"The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer.","date":"2023","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36922568","citation_count":35,"is_preprint":false},{"pmid":"36647288","id":"PMC_36647288","title":"PRMT1 driven PTX3 regulates ferritinophagy in glioma.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36647288","citation_count":34,"is_preprint":false},{"pmid":"32861926","id":"PMC_32861926","title":"PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells.","date":"2020","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/32861926","citation_count":33,"is_preprint":false},{"pmid":"32420808","id":"PMC_32420808","title":"LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32420808","citation_count":32,"is_preprint":false},{"pmid":"28655788","id":"PMC_28655788","title":"PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28655788","citation_count":32,"is_preprint":false},{"pmid":"32357521","id":"PMC_32357521","title":"Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32357521","citation_count":32,"is_preprint":false},{"pmid":"31235809","id":"PMC_31235809","title":"Hepatocyte PRMT1 protects from alcohol induced liver injury by modulating oxidative stress responses.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31235809","citation_count":32,"is_preprint":false},{"pmid":"37991725","id":"PMC_37991725","title":"PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37991725","citation_count":31,"is_preprint":false},{"pmid":"37938975","id":"PMC_37938975","title":"Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesis.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37938975","citation_count":31,"is_preprint":false},{"pmid":"33127433","id":"PMC_33127433","title":"Roles of protein arginine methyltransferase 1 (PRMT1) in brain development and disease.","date":"2020","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/33127433","citation_count":30,"is_preprint":false},{"pmid":"32415090","id":"PMC_32415090","title":"PRMT1 promotes neuroblastoma cell survival through ATF5.","date":"2020","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32415090","citation_count":30,"is_preprint":false},{"pmid":"35040433","id":"PMC_35040433","title":"Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35040433","citation_count":30,"is_preprint":false},{"pmid":"39042374","id":"PMC_39042374","title":"Arginine Methylation of DDX3 by PRMT1 Mediates Mitochondrial Homeostasis to Promote Breast Cancer Metastasis.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39042374","citation_count":29,"is_preprint":false},{"pmid":"38303029","id":"PMC_38303029","title":"TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38303029","citation_count":29,"is_preprint":false},{"pmid":"37005412","id":"PMC_37005412","title":"PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37005412","citation_count":29,"is_preprint":false},{"pmid":"31848151","id":"PMC_31848151","title":"PRMT1 Is Required for the Maintenance of Mature β-Cell Identity.","date":"2019","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/31848151","citation_count":29,"is_preprint":false},{"pmid":"35863589","id":"PMC_35863589","title":"PRMT1 suppresses doxorubicin-induced cardiotoxicity by inhibiting endoplasmic reticulum stress.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35863589","citation_count":29,"is_preprint":false},{"pmid":"35053470","id":"PMC_35053470","title":"PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35053470","citation_count":29,"is_preprint":false},{"pmid":"38460517","id":"PMC_38460517","title":"PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38460517","citation_count":28,"is_preprint":false},{"pmid":"36995937","id":"PMC_36995937","title":"CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36995937","citation_count":28,"is_preprint":false},{"pmid":"35921899","id":"PMC_35921899","title":"Protein arginine methyltransferase PRMT1 promotes adipogenesis by modulating transcription factors C/EBPβ and PPARγ.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35921899","citation_count":28,"is_preprint":false},{"pmid":"31787756","id":"PMC_31787756","title":"PRMT1 suppresses ATF4-mediated endoplasmic reticulum response in cardiomyocytes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31787756","citation_count":28,"is_preprint":false},{"pmid":"37564212","id":"PMC_37564212","title":"Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37564212","citation_count":27,"is_preprint":false},{"pmid":"36377249","id":"PMC_36377249","title":"Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/36377249","citation_count":26,"is_preprint":false},{"pmid":"37737256","id":"PMC_37737256","title":"Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37737256","citation_count":26,"is_preprint":false},{"pmid":"33208761","id":"PMC_33208761","title":"PRMT1 inhibition induces differentiation of colon cancer cells.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33208761","citation_count":26,"is_preprint":false},{"pmid":"35401831","id":"PMC_35401831","title":"Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35401831","citation_count":25,"is_preprint":false},{"pmid":"38326807","id":"PMC_38326807","title":"PRMT1 in human neoplasm: cancer biology and potential therapeutic target.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38326807","citation_count":24,"is_preprint":false},{"pmid":"30154485","id":"PMC_30154485","title":"PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice.","date":"2018","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30154485","citation_count":24,"is_preprint":false},{"pmid":"32563156","id":"PMC_32563156","title":"PRMT1 Is Critical for the Transcriptional Activity and the Stability of the Progesterone Receptor.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32563156","citation_count":23,"is_preprint":false},{"pmid":"39009589","id":"PMC_39009589","title":"PRMT1 promotes Warburg effect by regulating the PKM2/PKM1 ratio in non-small cell lung cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39009589","citation_count":22,"is_preprint":false},{"pmid":"34440533","id":"PMC_34440533","title":"Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34440533","citation_count":22,"is_preprint":false},{"pmid":"38401121","id":"PMC_38401121","title":"PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38401121","citation_count":21,"is_preprint":false},{"pmid":"36151091","id":"PMC_36151091","title":"TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36151091","citation_count":21,"is_preprint":false},{"pmid":"38605214","id":"PMC_38605214","title":"LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38605214","citation_count":20,"is_preprint":false},{"pmid":"40927753","id":"PMC_40927753","title":"PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.","date":"2025","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/40927753","citation_count":20,"is_preprint":false},{"pmid":"37269817","id":"PMC_37269817","title":"PRMT1 methylates METTL14 to modulate its oncogenic function.","date":"2023","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37269817","citation_count":20,"is_preprint":false},{"pmid":"38691454","id":"PMC_38691454","title":"PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38691454","citation_count":20,"is_preprint":false},{"pmid":"30741995","id":"PMC_30741995","title":"Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30741995","citation_count":20,"is_preprint":false},{"pmid":"37554218","id":"PMC_37554218","title":"PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the β-catenin pathway.","date":"2023","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37554218","citation_count":20,"is_preprint":false},{"pmid":"39201539","id":"PMC_39201539","title":"Role of PRMT1 and PRMT5 in Breast Cancer.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39201539","citation_count":19,"is_preprint":false},{"pmid":"34688662","id":"PMC_34688662","title":"Naturally occurring cancer-associated mutations disrupt oligomerization and activity of protein arginine methyltransferase 1 (PRMT1).","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34688662","citation_count":19,"is_preprint":false},{"pmid":"34516499","id":"PMC_34516499","title":"The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression.","date":"2021","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34516499","citation_count":19,"is_preprint":false},{"pmid":"32583741","id":"PMC_32583741","title":"SCYL1 arginine methylation by PRMT1 is essential for neurite outgrowth via Golgi morphogenesis.","date":"2020","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/32583741","citation_count":19,"is_preprint":false},{"pmid":"40446574","id":"PMC_40446574","title":"Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40446574","citation_count":18,"is_preprint":false},{"pmid":"35755248","id":"PMC_35755248","title":"Design and Synthesis of Novel PRMT1 Inhibitors and Investigation of Their Effects on the Migration of Cancer Cell.","date":"2022","source":"Frontiers in chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35755248","citation_count":17,"is_preprint":false},{"pmid":"29986157","id":"PMC_29986157","title":"Protein Arginine Methyltransferase PRMT1 Is Essential for Palatogenesis.","date":"2018","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/29986157","citation_count":16,"is_preprint":false},{"pmid":"29727702","id":"PMC_29727702","title":"Prmt1 regulates craniofacial bone formation upstream of Msx1.","date":"2018","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/29727702","citation_count":16,"is_preprint":false},{"pmid":"32011657","id":"PMC_32011657","title":"Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4).","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32011657","citation_count":16,"is_preprint":false},{"pmid":"37593409","id":"PMC_37593409","title":"Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation.","date":"2023","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/37593409","citation_count":15,"is_preprint":false},{"pmid":"33741434","id":"PMC_33741434","title":"mTOR regulates PRMT1 expression and mitochondrial mass through STAT1 phosphorylation in hepatic cell.","date":"2021","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33741434","citation_count":15,"is_preprint":false},{"pmid":"35226477","id":"PMC_35226477","title":"Functional Study of Leishmania braziliensis Protein Arginine Methyltransferases (PRMTs) Reveals That PRMT1 and PRMT5 Are Required for Macrophage Infection.","date":"2022","source":"ACS infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35226477","citation_count":15,"is_preprint":false},{"pmid":"35764172","id":"PMC_35764172","title":"A peptoid-based inhibitor of protein arginine methyltransferase 1 (PRMT1) induces apoptosis and autophagy in cancer cells.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35764172","citation_count":15,"is_preprint":false},{"pmid":"35885916","id":"PMC_35885916","title":"Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (PRMT1) Gene, Expressed in Breast Cancer Cells.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35885916","citation_count":15,"is_preprint":false},{"pmid":"33380261","id":"PMC_33380261","title":"Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5.","date":"2020","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33380261","citation_count":15,"is_preprint":false},{"pmid":"38724444","id":"PMC_38724444","title":"Towards the Targeted Protein Degradation of PRMT1.","date":"2024","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/38724444","citation_count":14,"is_preprint":false},{"pmid":"39817908","id":"PMC_39817908","title":"Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39817908","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49642,"output_tokens":14788,"usd":0.185373,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":27299,"output_tokens":6391,"usd":0.148135,"stage2_stop_reason":"end_turn"},"total_usd":0.333508,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Recombinant HRMT1L2 (PRMT1) protein exhibits arginine methyltransferase activity in vitro and complements a yeast HMT1 mutant strain in vivo, establishing it as a functional human arginine methyltransferase.\",\n      \"method\": \"In vitro methyltransferase assay with recombinant protein; yeast complementation assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay plus in vivo complementation, two orthogonal methods in a single study\",\n      \"pmids\": [\"9545638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PRMT1 binds specifically to the intracytoplasmic domain of the IFNAR-1 chain of the type I interferon receptor (not IFNAR-2 or PRMT2), and reduced PRMT1 expression diminishes the antiviral and antiproliferative effects of IFN-β.\",\n      \"method\": \"Co-immunoprecipitation; antisense-mediated knockdown with VSV replication assay and cell growth inhibition assay\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding demonstrated, functional knockdown with specific phenotypic readout, single lab\",\n      \"pmids\": [\"10090404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRMT1 and CARM1 cooperate as coactivators of STAT5-dependent transcription; cytokine stimulation induces a physical association between STAT5 and both PRMTs, and both enzymes are recruited to the CITED2 gene promoter as direct co-activators.\",\n      \"method\": \"siRNA double knockdown; cDNA microarray; ChIP; reporter gene assay; co-immunoprecipitation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP, co-IP, reporter assay, microarray), single lab\",\n      \"pmids\": [\"18413343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRMT1 physically interacts with orphan receptor TR3 and stabilizes TR3 protein (independent of methyltransferase activity), enhancing TR3 transcriptional activity; reciprocally, TR3 binding to the catalytic domain of PRMT1 inhibits PRMT1 methyltransferase activity, altering methylation of PRMT1 substrates STAT3 and Sam68.\",\n      \"method\": \"Co-immunoprecipitation; methyltransferase activity assay; luciferase reporter assay; TR3-knockdown cells and TR3-knockout mice\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction and enzymatic activity measured, in vivo validation in knockout mice, single lab\",\n      \"pmids\": [\"19095693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PRMT1 and PRMT2 directly interact, and this interaction stimulates PRMT1 methyltransferase activity (increased Vmax and altered Km); complex formation requires full-length active PRMT1 and the SH3 domain of PRMT2 contributes to a methylation-dependent interaction.\",\n      \"method\": \"Co-immunoprecipitation; bimolecular fluorescence complementation; in vitro methyltransferase assays; active-site mutagenesis and domain deletions\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted interaction and enzymatic assay with mutagenesis, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"21851090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRMT1 methylates RBM15 at R578, promoting its ubiquitylation by E3 ligase CNOT4 and subsequent proteasomal degradation; reduced RBM15 protein impairs recruitment of splicing factor SF3B1 to intronic regions of megakaryopoiesis genes (GATA1, RUNX1, TAL1, c-MPL), thereby regulating alternative splicing.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; ubiquitylation assay; RNA-IP; rescue experiments with RBM15 overexpression\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation, ubiquitylation assay, multiple binding assays, functional rescue, replicated across cell lines\",\n      \"pmids\": [\"26575292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRMT1 methylates EGFR at R198 and R200 of the extracellular domain, enhancing EGF binding, receptor dimerization, and downstream signaling; methylation-defective EGFR mutants reduce tumor growth and restore sensitivity to cetuximab.\",\n      \"method\": \"In vitro methylation assay; site-directed mutagenesis; binding assay; mouse orthotopic colorectal cancer xenograft model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, mutagenesis, in vivo xenograft validation, multiple orthogonal methods\",\n      \"pmids\": [\"26571401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRMT1 enzymatic activity is inhibited under oxidative conditions via cysteine oxidation to sulfenic acid (-SOH); this inhibition is reversible by reduction, representing a redox-sensitive regulatory mechanism distinct from changes in protein expression.\",\n      \"method\": \"In vitro methyltransferase activity assay; hydrogen peroxide dose-response; cysteine oxidation detection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mechanistic detail, single lab, single method type\",\n      \"pmids\": [\"25911106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRMT1 and PRMT8 act as selective modulators of retinoic acid receptor (RAR/RXR) transcriptional activity in neuronal differentiation; loss of either reduces nuclear arginine methylation and dysregulates neuronal gene expression, affecting neuronal cell fate.\",\n      \"method\": \"siRNA knockdown; RNA-seq; neuronal differentiation model of murine ESCs; electrophysiology\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with transcriptomic and functional readout, multiple methods, single lab\",\n      \"pmids\": [\"25388207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT1 methylates CDK4, preventing formation of the CDK4-Cyclin-D3 complex and thereby inducing cell cycle arrest in pre-B cells; BTG2 acts as an adaptor facilitating PRMT1 methylation of CDK4.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; cell cycle analysis; in vitro and in vivo proliferation assays with BCR-ABL1-transformed pre-B cells\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation of CDK4 confirmed, complex formation shown, in vivo functional validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28628091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT1 methylates the transcriptional co-activator Eya1, and loss of PRMT1 in muscle stem cells prevents Eya1 methylation, reducing Eya1 recruitment to the MyoD promoter and suppressing Eya1/Six1-dependent MyoD expression, thereby impairing muscle stem cell differentiation.\",\n      \"method\": \"In vitro methylation assay; conditional Pax7CreERT2-driven Prmt1 knockout; ChIP; co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation assay, conditional KO model, ChIP demonstrating mechanism, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27849571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT1 depletion impairs arginine methylation of the translation initiation complex, disrupting its assembly and inhibiting cap-dependent translation; this represents a critical vulnerability in p53-deficient cancer cells.\",\n      \"method\": \"shRNA screen; mechanistic proteomics; translation initiation complex assembly assay; in vitro and in vivo tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic depletion with proteomic pathway analysis and functional translation assay, single lab\",\n      \"pmids\": [\"28655788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PRMT1 methylates CaMKII at R9 and R275, inhibiting CaMKII activity; cardiac-specific PRMT1 deletion leads to CaMKII hyperactivation, dilated cardiomyopathy and heart failure, which is rescued by pharmacological CaMKII inhibition.\",\n      \"method\": \"Cardiac-specific Prmt1 knockout mice; in vitro methylation assay; co-immunoprecipitation; CaMKII activity assay; pharmacological rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation with site identification, conditional KO with clear phenotype, pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"30504773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PRMT1 methylates SMAD7 at the TGF-β receptor complex, promoting SMAD7 dissociation from receptors and enabling TGF-β-induced SMAD3 activation; this mechanism is required for TGF-β-induced EMT and epithelial stem-cell generation.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; siRNA knockdown; EMT and stem-cell functional assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation demonstrated, functional epistasis shown, single lab\",\n      \"pmids\": [\"29907569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GFI1 interacts with PRMT1 and its substrates MRE11 and 53BP1, enabling PRMT1 to bind and methylate these DNA repair proteins; GFI1 loss abolishes PRMT1-dependent methylation of MRE11 and 53BP1 and causes defective DNA damage response.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; GFI1 knockout T cells; ionizing radiation sensitivity assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate methylation demonstrated in vitro and in vivo, adaptor function shown by co-IP and KO, single lab\",\n      \"pmids\": [\"29651020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RANKL treatment increases PRMT1 expression and promotes its nuclear localization in bone marrow-derived macrophages via JNK-dependent signaling; PRMT1 directly interacts with NF-κB and regulates its transcriptional activity during osteoclastogenesis.\",\n      \"method\": \"siRNA knockdown; PRMT1 haploinsufficient cells; co-immunoprecipitation; TRAP staining; in vivo OVX mouse model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with defined cellular phenotype, co-IP for interaction, in vivo validation, single lab\",\n      \"pmids\": [\"30154485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 methylates FLT3-ITD at R972/R973; this methylation promotes AML maintenance and cross-talks with FLT3 phosphorylation at Y969; importantly, FLT3 methylation persists following kinase inhibitor treatment, indicating independence from kinase activity.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; PRMT1-knockout mouse; patient-derived xenograft and murine AML models; combined inhibitor treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation with site identification, PRMT1 KO mouse, PDX in vivo model, multiple orthogonal methods\",\n      \"pmids\": [\"31217189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 asymmetrically dimethylates UBAP2L at its RGG motif; increased arginine methylation of UBAP2L blocks its interactions with stress granule (SG) components (mRNPs, RBPs, ribosomal subunits), preventing SG assembly, while decreased methylation promotes SG assembly.\",\n      \"method\": \"In vitro methylation assay; stress granule assembly/disassembly assays; immunofluorescence; co-immunoprecipitation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation shown, SG functional consequence demonstrated, single lab with multiple methods\",\n      \"pmids\": [\"31114027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 methylates SRSF1, and this methylation is required for SRSF1 binding with RNA; in the absence of PRMT1, SRSF1 methylation and SRSF1-dependent splicing functions are impaired.\",\n      \"method\": \"In vitro methylation assay; RNA-binding assay; siRNA knockdown; splicing reporter assay\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro methylation mentioned but mechanistic detail is limited in the abstract; primarily correlation data\",\n      \"pmids\": [\"22839530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of PRMT1 sensitizes cells to PRMT5 inhibition; MTAP-deleted cells with attenuated PRMT5-MEP50 signaling are more sensitive to PRMT1 inhibition, demonstrating functional redundancy between PRMT1 (asymmetric methylation) and PRMT5 (symmetric methylation) pathways.\",\n      \"method\": \"CRISPR/Cas9 genetic screen; pharmacological inhibitor combination; cell viability assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen with pharmacological validation, pathway epistasis established, single lab\",\n      \"pmids\": [\"30916320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 is constitutively bound to IGF-1R and becomes activated upon IGF-1 stimulation; activated PRMT1 methylates ERα at R260, triggering formation of the mERα/Src/PI3K complex and non-genomic IGF-1 signaling in breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; PRMT1 inhibition/knockdown; signaling pathway analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding and activation shown by co-IP, methylation confirmed in vitro and in cells, single lab\",\n      \"pmids\": [\"30692633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 methylates ATF4 at R239, stabilizing ATF4 protein; ATF4 methylation-deficient mutant R239K exacerbates ER stress and apoptosis in cardiomyocytes; PRMT1 null hearts show exacerbated ER stress.\",\n      \"method\": \"In vitro methylation assay; site-directed mutagenesis; PRMT1 conditional knockout heart; ER stress markers\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation with mutagenesis, conditional KO model, mechanistic protein stability assay, single lab multiple orthogonal methods\",\n      \"pmids\": [\"31787756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 is required for maintaining β-cell identity; PRMT1-dependent H4R3me2a increases chromatin accessibility at CTCF and β-cell transcription factor binding sites, as revealed by ChIP-seq and ATAC-seq in β-cell-specific Prmt1 knockout mice.\",\n      \"method\": \"β-cell-specific Prmt1 knockout; ChIP-seq; ATAC-seq; gene expression profiling\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — conditional KO with genome-wide chromatin accessibility profiling, mechanistic link established between H4R3me2a and chromatin opening, multiple orthogonal methods\",\n      \"pmids\": [\"31848151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Deep proteomic methylation profiling identified 18 high-confidence PRMT1 substrates; PRMT1 knockdown caused significant loss of asymmetric dimethylarginine (ADMA) marks on 78 proteins enriched for mRNA metabolic processes; some sites (e.g., HNRNPA1 R206) switch from ADMA to SDMA upon PRMT1 knockdown, revealing dynamic interplay between methyltransferases.\",\n      \"method\": \"Immunoaffinity purification and strong cation exchange enrichment; mass spectrometry; PRMT1 knockdown\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic proteomic approach with two orthogonal enrichment methods, PRMT1 KD validated, single lab\",\n      \"pmids\": [\"31451547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Alcohol induces PRMT1 dephosphorylation at S297; phosphorylation at S297 is necessary for PRMT1-dependent protein arginine methylation and regulation of pro-inflammatory and pro-apoptotic gene expression, while oxidative stress response gene regulation is phosphorylation-independent.\",\n      \"method\": \"AAV-Cre-mediated hepatocyte-specific PRMT1 knockout; phosphorylation mimic/null mutants (S297A, S297D); gene expression analysis; in vitro methyltransferase assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with phospho-mutant rescue, in vivo mouse model, single lab\",\n      \"pmids\": [\"31235809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 is recruited to chromatin by DNA-PK in response to cisplatin; DNA-PK phosphorylates PRMT1, directing its enzymatic activity toward H4R3 (producing H4R3me2a) at pro-inflammatory gene promoters, thereby sustaining the senescence-associated secretory phenotype (SASP).\",\n      \"method\": \"Mass spectrometry-based proteomics; co-immunoprecipitation; ChIP; H4R3me2a chromatin profiling; clonogenic assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for DNA-PK/PRMT1 interaction, ChIP for chromatin recruitment, functional SASP readout, single lab\",\n      \"pmids\": [\"31995759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 regulates Mdm4 pre-mRNA splicing; loss of PRMT1 shifts Mdm4 splicing toward a shorter isoform, leading to p53 accumulation, enhanced Slug degradation, and blockade of EMT in epicardial cells.\",\n      \"method\": \"Epicardial-specific Prmt1 deletion; scRNA-seq; splicing analysis; p53 pathway readouts; in vivo epicardial invasion assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined splicing and signaling mechanism, in vivo validation, single lab\",\n      \"pmids\": [\"32521264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 methylates EZH2 at R342 (meR342-EZH2); this methylation inhibits CDK1-mediated phosphorylation at EZH2 T345 and T487, thereby attenuating TRAF6-mediated ubiquitylation and increasing EZH2 protein stability.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; phosphorylation and ubiquitylation assays; site-directed mutagenesis\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic cross-talk with phosphorylation and ubiquitylation established, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"32895488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 methylates SCYL1 at the γ2-COP binding site; this methylation is required for SCYL1 interaction with γ2-COP and COPI vesicle function; PRMT1 colocalizes with SCYL1 in the Golgi fraction, and inhibition of PRMT1 causes abnormal Golgi morphology and impairs axon and dendrite outgrowth.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; subcellular fractionation; siRNA knockdown; neurite outgrowth assay; rescue with methylation-site SCYL1 mutant\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation, Golgi colocalization by fractionation, binding assay, siRNA KD with mutant rescue, multiple methods, single lab\",\n      \"pmids\": [\"32583741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 suppresses doxorubicin-induced cardiotoxicity; doxorubicin induces PRMT1 translocation to the endoplasmic reticulum, where PRMT1 methylates ATF4 to suppress the PERK/ATF4/CHOP proapoptotic ER stress pathway.\",\n      \"method\": \"PRMT1 overexpression/depletion in H9c2 cardiomyocytes; subcellular fractionation/translocation assay; ER stress marker analysis; in vitro methylation assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ER translocation shown by fractionation, ATF4 methylation linked to ER stress suppression, single lab\",\n      \"pmids\": [\"35863589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1 methylates NONO at R251; this asymmetric dimethylation promotes colorectal cancer cell proliferation, migration, and invasion; NONO R251K mutant cells show reduced malignant phenotype.\",\n      \"method\": \"Mass spectrometry; in vitro methylation assay; NONO R251K mutant cell lines; PRMT1 knockdown and pharmacological inhibition; xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation with MS validation, site mutagenesis with functional phenotype, in vivo xenograft, single lab\",\n      \"pmids\": [\"33420374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1-mediated H4R3me2a directly recruits SMARCA4 (an ATPase subunit of the SWI/SNF complex) to chromatin; SMARCA4 acts as a novel effector of H4R3me2a and cooperates with PRMT1 to activate EGFR and TNS4 transcription in colorectal cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; ChIP; ChIP-seq; cell proliferation/migration assays; in vivo CRC mouse model\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ChIP-seq demonstrate direct H4R3me2a–SMARCA4 recruitment, in vivo model, single lab\",\n      \"pmids\": [\"33853662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1 inhibition in PDAC impairs RNA metabolism including splicing, alternative polyadenylation, and transcription termination, causing downregulation of DNA damage response pathways and promoting genomic instability.\",\n      \"method\": \"RNAi in vivo functional genomics; proteomic and transcriptomic analyses; pharmacological PRMT1 inhibition; patient-derived PDAC models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide transcriptomic/proteomic mechanistic analysis, in vivo RNAi screen validation, single lab\",\n      \"pmids\": [\"34330913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1 methylates EZH2 at R342, promoting PRC2 complex assembly by facilitating EZH2 interaction with SUZ12 and preventing AMPKα1-mediated phosphorylation at T311; this results in enhanced H3K27me3 at P16 and P21 promoters and promotes breast cancer cell proliferation.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; ChIP; site-directed mutagenesis; in vitro and in vivo proliferation assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation, mechanistic cross-talk with phosphorylation and PRC2 assembly shown, ChIP validation, single lab\",\n      \"pmids\": [\"34775498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1 promotes TBK1 activation by directly interacting with TBK1 and catalyzing asymmetric methylation at R54, R134, and R228; this methylation enhances TBK1 oligomerization and subsequent TBK1 phosphorylation, promoting type I interferon production; myeloid-specific Prmt1 KO mice are more susceptible to viral infection.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; site-directed mutagenesis; myeloid-specific Prmt1 knockout mice; viral infection model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation with site identification, conditional KO mouse, in vivo viral infection phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"34551290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Naturally occurring cancer-associated mutations in the PRMT1 dimerization arm (W215L, Y220N, M224V) disrupt oligomer formation and substantially impair SAM binding and methyltransferase activity, demonstrating that dimerization through the dimerization arm is required for PRMT1 catalytic function.\",\n      \"method\": \"Site-directed mutagenesis; analytical ultracentrifugation; native PAGE; in vitro methyltransferase activity assay; molecular dynamics simulations\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with biophysical and activity assays, mechanistic characterization of dimerization-activity link, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34688662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Wnt activation upregulates PRMT1 expression in CD8+ T cells; PRMT1-mediated H4R3me2a deposition at the IL-2 promoter is required for Wnt-induced T cell polyfunctionality and IL-2 production; PRMT1 inhibition abrogates the polyfunctionality effect.\",\n      \"method\": \"Chromatin immunoprecipitation; PRMT1 inhibition; gene expression profiling; cytokine production assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates mechanistic link between H4R3me2a and IL-2 promoter, inhibitor validates PRMT1 requirement, single lab\",\n      \"pmids\": [\"35040433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRMT1 promotes adipogenesis by catalyzing H4R3me2a to upregulate PPARγ expression; PRMT1 also stabilizes C/EBPβ protein by decreasing the E3 ubiquitin ligase Smurf2 levels, and interacts with C/EBPβ to promote its phosphorylation.\",\n      \"method\": \"Gain and loss of function (siRNA/overexpression); H4R3me2a ChIP; co-immunoprecipitation; ubiquitylation assay; adipogenesis assay in 3T3-L1 and C3H10T1/2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — histone modification shown by ChIP, protein stability mechanism by ubiquitylation assay, multiple substrates, single lab\",\n      \"pmids\": [\"35921899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRMT1 methylates SRSF1, which is critical for SRSF1 phosphorylation, SRSF1 binding to RNA, and exon inclusion; PRMT1 overexpression in breast tumors is associated with increased SRSF1 arginine methylation and aberrant exon inclusion patterns that drive cancer cell growth.\",\n      \"method\": \"PRMT1 methylome profiling; in vitro methylation assay; RNA binding assay; splicing reporter; PRMT1 inhibitor iPRMT1; breast cancer cell growth assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation, RNA binding assay, splicing functional readout, pharmacological and genetic validation, single lab with multiple methods\",\n      \"pmids\": [\"37938975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 methylates cGAS at conserved R133, preventing cGAS dimerization and suppressing cGAS/STING innate immune signaling in cancer cells; genetic or pharmacological PRMT1 ablation activates cGAS/STING-dependent type I and II interferon responses and increases tumor-infiltrating lymphocytes.\",\n      \"method\": \"In vitro methylation assay; site-directed mutagenesis; cGAS dimerization assay; cGAS/STING pathway reporter; in vivo tumor model with anti-PD-1 combination\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation at defined site, mechanistic dimerization assay, in vivo immunotherapy combination, multiple orthogonal methods\",\n      \"pmids\": [\"37193698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 methylates PHGDH at R236, activating PHGDH catalytic activity and promoting serine biosynthesis, oxidative stress resistance, and HCC tumor growth; blocking PHGDH methylation with a TAT-tagged peptide inhibits serine synthesis and restrains HCC growth in PDX and xenograft models.\",\n      \"method\": \"In vitro methylation assay; mass spectrometry; PHGDH activity assay; PDX and xenograft mouse models; metabolomics\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation with site identification, enzyme activity assay, in vivo PDX model, mechanistic peptide rescue, multiple orthogonal methods\",\n      \"pmids\": [\"36823188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK5 phosphorylates PRMT1 at S307, promoting its translocation from nucleus to cytoplasm and lysosome; cytoplasmic PRMT1 then methylates WDR24 (a GATOR2 complex component) to activate mTORC1 signaling in response to amino acids.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation; in vitro methylation assay; mTORC1 signaling assay; xenograft tumor model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation-driven translocation shown by fractionation, substrate methylation confirmed, pathway activation measured, single lab\",\n      \"pmids\": [\"36995937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 methylates WTAP (a key m6A methyltransferase complex component); WTAP methylation promotes m6A modification of NDUFS6 mRNA, activating oxidative phosphorylation in multiple myeloma cells.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; m6A sequencing; PRMT1 knockdown; OXPHOS functional assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation of WTAP, m6A downstream effect shown, single lab\",\n      \"pmids\": [\"37558663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 methylates RIP3 at R486 (R479 in mouse), inhibiting RIP3 interaction with RIP1 and suppression of the RIP1-RIP3 necrosome complex, thereby blocking RIP3 phosphorylation and necroptosis activation; methylation-deficient RIP3 promotes necroptosis and tumor immune escape.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; RIP3 phosphorylation assay; MDSC infiltration assay; clinical sample analysis with RIP3 di-methylation-specific antibody\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic interaction disruption shown, functional necroptosis assay, single lab\",\n      \"pmids\": [\"37005412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 methylates BRD4 at R179/R181/R183 (antagonized by JMJD6 demethylase); PRMT1-mediated BRD4 methylation promotes BRD4 phosphorylation and ovarian cancer invasion; BRD4 R179/181/183K mutant cells show reduced metastasis.\",\n      \"method\": \"In vitro methylation assay; site-directed mutagenesis; co-immunoprecipitation; JMJD6 demethylation assay; invasion and migration assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation with site identification, writer/eraser pair demonstrated, functional mutagenesis, single lab\",\n      \"pmids\": [\"37737256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1-dependent H4R3me2a at the Dnmt1 enhancer region maintains DNMT1 expression; PRMT1 deficiency reduces DNMT1 levels, activating endogenous retroviral element (ERV) transcription and double-stranded RNA production, which stimulates interferon signaling and anti-tumor CD8+ T cell responses.\",\n      \"method\": \"ChIP; PRMT1 knockout; DNMT1 expression analysis; ERV transcription assay; in vivo tumor model with anti-PD-1\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP links H4R3me2a to DNMT1 enhancer, mechanistic pathway validated in vivo, single lab\",\n      \"pmids\": [\"37991725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 promotes c-Fos protein stability by methylating c-Fos at R287, protecting it from autophagic degradation; PRMT1-mediated methylation enhances AP-1 transcriptional activity and promotes gastric tumorigenesis.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; autophagy flux assay; PRMT1 knockdown; c-Fos stability assay\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation, protein stability mechanism via autophagy shown, single lab\",\n      \"pmids\": [\"37564212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT1 asymmetrically methylates METTL14 at two major arginine residues in its C-terminal RGG repeats; this methylation is recognized by reader protein SPF30 and is essential for METTL14 function in catalyzing m6A modification.\",\n      \"method\": \"In vitro methylation assay; co-immunoprecipitation; m6A modification assay; PRMT1 inhibitor MS023; cell proliferation assay\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation, reader identification, downstream m6A effect shown, single lab\",\n      \"pmids\": [\"37269817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FBXO7 binds PRMT1 and promotes its K37 ubiquitination and proteasomal degradation, thereby suppressing PHGDH arginine methylation/activation and serine synthesis in HCC; FBXO7 is downregulated in human HCC and inversely correlates with PRMT1 protein levels.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitylation assay; PHGDH activity assay; in vitro and in vivo HCC models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitylation site identified, functional consequence on downstream methylation shown, in vivo validation, single lab\",\n      \"pmids\": [\"38839752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT1 methylates PHGDH at R54 and R20 (and also PFKFB3 and PKM2), stabilizing PHGDH by suppressing polyubiquitination and activating it by stabilizing 3-phosphoglycerate binding; this drives serine synthesis pathway flux, increases citrate/palmitate via fatty acid synthase, and promotes chemoresistance in TNBC.\",\n      \"method\": \"In vitro methylation assay; 13C metabolic flux analysis; site mutagenesis; protein stability assay; FASN inhibition; clinical specimen IHC with imaging mass spectrometry\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation at defined sites, metabolic flux analysis, mutagenesis, clinical tissue validation, multiple orthogonal methods\",\n      \"pmids\": [\"38383964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT1 methylates PGK1 at R206; this meR206-PGK1 enhances phosphorylation at S203, inhibiting mitochondrial function and promoting aerobic glycolysis in colorectal cancer cells.\",\n      \"method\": \"In vitro methylation assay; phosphorylation assay; mitochondrial function assay; glycolysis assay; clinical tissue correlation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation at defined site, mechanistic cross-talk with phosphorylation shown, functional metabolic readout, single lab\",\n      \"pmids\": [\"38402202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT1 methylates DDX3 to enhance its protein stability and prevent proteasomal degradation; stabilized DDX3 translocates to mitochondria and facilitates PINK1 translation in response to mitochondrial stress, coordinating mitophagy and mitochondrial biogenesis to support breast cancer metastasis.\",\n      \"method\": \"In vitro methylation assay; protein stability assay; mitochondrial fractionation; PINK1 translation assay; in vivo metastasis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation, mitochondrial translocation shown by fractionation, translation assay, in vivo metastasis, single lab\",\n      \"pmids\": [\"39042374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"p53 activation under glucose-deficient conditions suppresses USP7 and promotes polyubiquitin-dependent degradation of PRMT1; melatonin-mediated reduction of glucose uptake downregulates PRMT1 via this p53-USP7 axis in p53 wild-type NSCLC.\",\n      \"method\": \"PRMT1 degradation assay; USP7 inhibitor; p53 activation experiments; cell viability assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanism inferred from inhibitor studies and expression analysis, limited direct biochemical demonstration in abstract\",\n      \"pmids\": [\"39009589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT1 suppresses IFNγ-induced MHC-I expression by limiting STAT1 expression and activation; PRMT1 knockout or pharmacological inhibition (GSK3368715) elevates STAT1 and MHC-I, enhancing CD8+ T cell-mediated tumor killing and potentiating anti-PD-1 immunotherapy.\",\n      \"method\": \"CRISPR-Cas9 epigenetic screen; PRMT1 KO; pharmacological inhibition; STAT1 expression and phosphorylation analysis; CD8+ T cell cytotoxicity assay; in vivo anti-PD-1 combination\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen with KO validation, STAT1/MHC-I mechanistic link, in vivo immunotherapy confirmation, single lab\",\n      \"pmids\": [\"38401121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT1 methylates PARP1; this methylation promotes PARP1-dependent DNA damage repair and activates NF-κB (P65) signaling, enhancing cancer cell stemness and immune suppression, thereby driving chemoresistance and lung metastasis in TNBC.\",\n      \"method\": \"Mass spectrometry; co-immunoprecipitation; NF-κB signaling assay; in vitro and in vivo metastasis and chemoresistance assays\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — interaction validated by MS and co-IP, downstream pathway effects shown, but detailed methylation site and direct mechanistic validation limited in abstract\",\n      \"pmids\": [\"40927753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRMT1 methylates TDP-43 at R293; R293 methylation permits TDP-43 liquid-liquid phase separation (LLPS) and reduces pathological TDP-43 aggregation; S292 phosphorylation (by p38α) reduces R293 methylation, establishing reciprocal cross-talk between p38α-mediated phosphorylation and PRMT1-mediated methylation in controlling TDP-43 proteinopathy.\",\n      \"method\": \"In vitro methylation assay; site-directed mutagenesis; LLPS assay; TDP-43 aggregation assay; ALS patient-derived motor neurons; p38α inhibition\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation at defined site, LLPS assay, cross-talk with phosphorylation demonstrated by mutagenesis, ALS patient cell validation, multiple orthogonal methods\",\n      \"pmids\": [\"39817908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT1 is required for PRMT1-dependent expression of FEN1 (a DNA repair endonuclease) via post-translational modification; elevated PRMT1 maintains high FEN1 levels, contributing to DNA repair capacity and drug resistance in lung cancer cells.\",\n      \"method\": \"PRMT1 knockdown; post-translational modification analysis; FEN1 expression and activity assay; drug resistance assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — relationship between PRMT1 and FEN1 shown but mechanism of PTM-driven FEN1 upregulation not fully detailed in abstract\",\n      \"pmids\": [\"32861926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EphA2 directly interacts with PRMT1 (by co-IP and GST pulldown), increases PRMT1 expression and activity; PRMT1 in turn methylates SOX2, promoting stemness and chemoresistance in small-cell lung cancer.\",\n      \"method\": \"Co-immunoprecipitation; GST pulldown; PRMT1 activity assay; in vitro methylation of SOX2; PDX model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal pulldown for interaction, in vitro SOX2 methylation, in vivo PDX validation, single lab\",\n      \"pmids\": [\"36377249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRMT1 promotes hepatic fatty acid oxidation to prevent diet-induced steatosis through methyltransferase activity-dependent induction of PGC-1α mRNA expression via HNF-4α recruitment to the PGC-1α promoter; methyltransferase-defective PRMT1G80R fails to alleviate steatosis.\",\n      \"method\": \"AAV-mediated hepatic PRMT1 overexpression/knockdown; PRMT1G80R catalytic mutant; ChIP (HNF-4α at PGC-1α promoter); fatty acid oxidation assay; diet-induced obese mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic mutant distinguishes methyltransferase-dependent effects, ChIP mechanistic evidence, in vivo mouse model, single lab\",\n      \"pmids\": [\"35401831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TIPE1 binds to the catalytic domain of PRMT1 and inhibits PRMT1-mediated asymmetric dimethylation of STAT3 at R688; loss of this methylation decreases STAT3 transactivation and suppresses osteosarcoma malignancy.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; STAT3 transactivation assay; TIPE1 overexpression/knockdown; in vivo osteosarcoma model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic domain interaction shown, in vitro methylation of STAT3, in vivo model, single lab\",\n      \"pmids\": [\"36151091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structures of CARM1 and PRMT1 bound to bisubstrate inhibitors reveal that a residue differing between CARM1 (Asn-265) and PRMT1 (Tyr-160) affects the side chain conformation of the catalytically important neighboring glutamate; mutagenesis confirms this residue contributes to differential inhibitor binding.\",\n      \"method\": \"X-ray crystallography; isothermal titration calorimetry; methyltransferase activity assay; site-directed mutagenesis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of PRMT1 active site with inhibitors, ITC binding measurement, mutagenesis validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32011657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"H4 Ser-1 phosphorylation inhibits PRMT1-catalyzed asymmetric dimethylation of H4R3; H4K5 acetylation reduces PRMT1 catalytic efficiency while enhancing PRMT5-mediated symmetric dimethylation at the same site, revealing that local histone modifications regulate PRMT1 substrate selectivity.\",\n      \"method\": \"In vitro methyltransferase assay using synthetic modified H4 peptides; kinetic analysis\",\n      \"journal\": \"Epigenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with modified substrates, kinetic characterization, single lab\",\n      \"pmids\": [\"33380261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LPCAT2 regulates acetylation of PRMT1 at K145, arresting PRMT1 in the cytoplasm of CRC cells; this prevents PRMT1-mediated nuclear activation of the SLC7A11 promoter, thereby reducing SLC7A11 expression, increasing lipid peroxidation, and inducing ferroptosis.\",\n      \"method\": \"scRNA-seq; co-immunoprecipitation; PRMT1 acetylation assay; SLC7A11 promoter luciferase assay; LPCAT2 knockout mice; ferroptosis assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — K145 acetylation–nuclear exclusion mechanism shown, promoter assay, in vivo KO model, single lab\",\n      \"pmids\": [\"38605214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In gemcitabine-treated PDAC cells, PRMT1 translocates to the nucleus where its methyltransferase activity limits assembly of chromatin-bound MAFF/BACH1 transcriptional complexes; disrupting this axis delays acquired gemcitabine resistance.\",\n      \"method\": \"Genetic and pharmacological PRMT1 inhibition; Cut&Tag chromatin profiling (H3K27Ac, MAFF, BACH1); MAFF genetic silencing; gemcitabine resistance assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear translocation shown, chromatin occupancy profiling mechanistic, in vivo PDX validation, single lab\",\n      \"pmids\": [\"38691454\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRMT1 is the predominant type I protein arginine methyltransferase in mammals that catalyzes monomethylation and asymmetric dimethylation of arginine residues in histones (notably H4R3me2a) and a broad range of non-histone substrates—including RBM15, EGFR, EZH2, FLT3, CaMKII, TBK1, cGAS, PHGDH, PGK1, SMAD7, CDK4, Eya1, SCYL1, UBAP2L, ATF4, SRSF1, TDP-43, and many others—thereby regulating transcription, RNA splicing, signal transduction, DNA damage response, innate immunity, metabolic reprogramming, and cell fate determination; its enzymatic activity depends on homodimerization through a dimerization arm, is stimulated by interaction with PRMT2 and inhibited by oxidation of active-site cysteines or binding of TR3 to its catalytic domain, and is controlled by upstream post-translational modifications including CDK5-mediated phosphorylation at S307 (promoting cytoplasmic/lysosomal translocation) and p53/USP7-mediated ubiquitin-dependent degradation, with FBXO7 targeting K37 for proteasomal degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRMT1 is the predominant mammalian type I protein arginine methyltransferase, catalyzing arginine monomethylation and asymmetric dimethylation of histone and non-histone substrates to regulate transcription, RNA processing, signal transduction, DNA damage response, innate immunity, and metabolic reprogramming [#0, #23]. Its catalytic activity requires homodimerization through a dimerization arm—cancer-associated mutations in this arm (W215L, Y220N, M224V) abolish oligomer formation and impair SAM binding and turnover [#35]—and is allosterically stimulated by direct interaction with PRMT2 [#4] while being repressed by reversible oxidation of active-site cysteines to sulfenic acid [#7] and by TR3 binding to the catalytic domain [#3]. On chromatin, PRMT1 deposits H4R3me2a to open chromatin and drive lineage- and stimulus-specific transcriptional programs, recruiting the SWI/SNF ATPase SMARCA4 as an effector [#31], maintaining DNMT1 enhancer activity to silence endogenous retroviruses [#45], and sustaining β-cell identity, adipogenesis, and inducible cytokine genes [#22, #37, #36]. Beyond histones, PRMT1 methylates a large repertoire of substrates—including EGFR, FLT3-ITD, CaMKII, SMAD7, EZH2, CDK4, cGAS, TBK1, PHGDH, PGK1, ATF4, SRSF1, and TDP-43—frequently engaging in cross-talk with phosphorylation, ubiquitylation, and other modifications to control protein stability, activity, complex assembly, and localization [#6, #16, #12, #27, #39, #34, #40, #55]. Many substrates are accessed through adaptor proteins (BTG2 for CDK4, GFI1 for MRE11/53BP1) [#9, #14], and substrate selectivity at H4R3 is tuned by neighbouring histone marks such as H4S1 phosphorylation and H4K5 acetylation [#61]. PRMT1 itself is positioned by upstream signaling: CDK5 phosphorylation at S307 drives nucleocytoplasmic/lysosomal translocation toward mTORC1 activation [#41], K145 acetylation arrests it in the cytoplasm [#62], and its abundance is set by FBXO7-mediated K37 ubiquitylation and p53/USP7-dependent degradation [#48, #52]. Through these activities PRMT1 functions as a context-dependent driver of cancer cell proliferation, metabolic flux, chemoresistance, and immune evasion, and conversely protects cardiomyocytes from CaMKII hyperactivation and ER stress [#49, #53, #12, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the founding identity of the human protein as a bona fide arginine methyltransferase rather than an uncharacterized ORF.\",\n      \"evidence\": \"In vitro methyltransferase assay with recombinant protein plus complementation of a yeast HMT1 mutant\",\n      \"pmids\": [\"9545638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological substrates\", \"No structure or catalytic mechanism defined\", \"Symmetric vs asymmetric product specificity not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked PRMT1 to a defined receptor pathway by showing it binds the IFNAR-1 cytoplasmic tail and supports type I interferon responses.\",\n      \"evidence\": \"Co-IP with IFNAR chains plus antisense knockdown with VSV and growth assays\",\n      \"pmids\": [\"10090404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No methylation substrate at the receptor identified\", \"Binding specificity not structurally mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined PRMT1 as a transcriptional coactivator recruited to target promoters and as a target of allosteric inhibition by an interacting orphan receptor.\",\n      \"evidence\": \"ChIP, reporter assays, and co-IP for STAT5/CITED2 coactivation; reciprocal TR3 interaction with catalytic-domain inhibition and substrate methylation changes\",\n      \"pmids\": [\"18413343\", \"19095693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct histone marks at coactivated promoters not measured in STAT5 work\", \"TR3 inhibitory binding site not mapped at residue level\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed PRMT1 activity is positively regulated by protein-protein interaction, establishing PRMT2 as an allosteric stimulator.\",\n      \"evidence\": \"Co-IP, BiFC, in vitro kinetics with domain deletions and active-site mutagenesis\",\n      \"pmids\": [\"21851090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of PRMT1-PRMT2 modulation not defined\", \"No structure of the stimulated complex\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Expanded PRMT1 into non-histone substrate biology, demonstrating methylation that controls substrate stability, receptor signaling, and splicing-factor function.\",\n      \"evidence\": \"In vitro methylation, mutagenesis, ubiquitylation/RNA-IP/rescue, and xenografts for RBM15 (R578) and EGFR (R198/R200)\",\n      \"pmids\": [\"26575292\", \"26571401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of methylation-coupled degradation across substrates unknown\", \"Extracellular EGFR methylation topology not structurally explained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified redox sensing as a post-translational control of PRMT1, distinct from expression-level regulation.\",\n      \"evidence\": \"In vitro activity assay with H2O2 dose-response and reversible cysteine oxidation detection\",\n      \"pmids\": [\"25911106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Oxidized cysteine residues not definitively mapped to active site\", \"In vivo redox regulation not demonstrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated adaptor-dependent substrate selection and lineage-specific transcriptional control, with in vivo conditional-knockout validation.\",\n      \"evidence\": \"BTG2-facilitated CDK4 methylation with cell-cycle assays; conditional Prmt1 KO with ChIP linking Eya1 methylation to MyoD induction\",\n      \"pmids\": [\"28628091\", \"27849571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methylated residues on CDK4 and Eya1 not fully mapped\", \"How adaptors confer specificity mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established PRMT1 as a regulator of signaling, DNA repair, and developmental transitions through substrate methylation and adaptor recruitment, with physiological consequences in heart.\",\n      \"evidence\": \"Cardiac KO with CaMKII methylation and pharmacological rescue; SMAD7 methylation in TGF-β/EMT; GFI1-dependent methylation of MRE11/53BP1\",\n      \"pmids\": [\"30504773\", \"29907569\", \"29651020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MRE11/53BP1 methylation sites and DDR mechanism not fully defined\", \"SMAD7 methylation site not pinpointed in this study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined PRMT1 as a global regulator of RNA metabolism and a context-specific cancer dependency, and quantified its methylproteome.\",\n      \"evidence\": \"Proteomic ADMA profiling (18 high-confidence substrates; ADMA-to-SDMA switching), translation-initiation and FLT3-ITD/AML KO models, CRISPR PRMT1/PRMT5 synthetic lethality\",\n      \"pmids\": [\"31451547\", \"28655788\", \"31217189\", \"30916320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of most ADMA sites untested\", \"Mechanism of ADMA/SDMA scavenging interplay incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended PRMT1 control to stress-granule dynamics, nuclear receptor non-genomic signaling, ER-stress protein stability, and chromatin accessibility for cell identity.\",\n      \"evidence\": \"UBAP2L RGG methylation/SG assays; IGF-1R-bound PRMT1 methylating ERα R260; ATF4 R239 methylation with cardiac KO; β-cell KO with ChIP-seq/ATAC-seq linking H4R3me2a to open chromatin\",\n      \"pmids\": [\"31114027\", \"30692633\", \"31787756\", \"31848151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single enzyme balances nuclear vs cytoplasmic substrate pools not resolved here\", \"Direct vs indirect chromatin opening by H4R3me2a not separable in KO\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the structural basis of PRMT1 inhibitor selectivity and dimerization-dependent catalysis, and showed neighbouring histone marks tune substrate choice.\",\n      \"evidence\": \"Crystal structures/ITC of PRMT1 with bisubstrate inhibitors; dimerization-arm mutants with biophysics and activity; modified H4 peptide kinetics\",\n      \"pmids\": [\"32011657\", \"33380261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full enzyme-substrate complex structures for non-histone substrates lacking\", \"Dynamics of dimer assembly in cells not measured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed PRMT1 chromatin recruitment and translocation are signal-driven, coupling DNA damage and Golgi/secretory functions to its methyltransferase activity.\",\n      \"evidence\": \"DNA-PK-mediated recruitment/phosphorylation directing H4R3me2a at SASP genes; SCYL1 methylation with Golgi colocalization and neurite-outgrowth rescue; Mdm4 splicing control in epicardium\",\n      \"pmids\": [\"31995759\", \"32583741\", \"32521264\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PRMT1 phosphosite targeted by DNA-PK not identified\", \"SCYL1 methylation site not fully defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Consolidated PRMT1 as a hub coupling histone marks to effector recruitment and as a stabilizer/activator of chromatin and immune-signaling proteins.\",\n      \"evidence\": \"H4R3me2a-dependent SMARCA4 recruitment; EZH2 R342 methylation cross-talk stabilizing protein and promoting PRC2 assembly; TBK1 methylation (R54/R134/R228) with myeloid KO viral susceptibility; PDAC RNA-metabolism dependency\",\n      \"pmids\": [\"33853662\", \"32895488\", \"34775498\", \"34551290\", \"34330913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How H4R3me2a is read by SMARCA4 structurally unknown\", \"Substrate prioritization during infection not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded PRMT1 into immune-cell programming, adipogenesis, hepatic metabolism, and additional substrate-stability/stemness axes.\",\n      \"evidence\": \"H4R3me2a at IL-2 promoter for CD8+ polyfunctionality; PPARγ/C/EBPβ control in adipogenesis; catalytic-mutant-validated PGC-1α/HNF-4α hepatic FAO; EphA2-PRMT1-SOX2 stemness\",\n      \"pmids\": [\"35040433\", \"35921899\", \"35401831\", \"36377249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect targets in metabolic programs incompletely separated\", \"SOX2 methylation site not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined PRMT1 as a brake on innate-immune and necroptotic signaling and a driver of metabolic and m6A-related reprogramming, with translational implications for immunotherapy.\",\n      \"evidence\": \"cGAS R133 methylation blocking dimerization/STING; RIP3 R486 methylation suppressing necrosome; PHGDH R236 activation; WTAP and METTL14 methylation regulating m6A; DNMT1-enhancer H4R3me2a controlling ERV/IFN; BRD4, c-Fos, NONO methylation\",\n      \"pmids\": [\"37193698\", \"37005412\", \"36823188\", \"37558663\", \"37269817\", \"37991725\", \"37737256\", \"37564212\", \"33420374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity that determines which substrate dominates in a given tumor context unresolved\", \"Reader-mediated outputs (e.g., SPF30) functionally underexplored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped upstream control of PRMT1 abundance and localization and detailed its role in metabolic flux, mitochondrial fate, and immune evasion.\",\n      \"evidence\": \"FBXO7 K37 ubiquitylation; CDK5-S307 phosphorylation driving translocation and WDR24/mTORC1 activation; K145 acetylation (LPCAT2) cytoplasmic arrest controlling SLC7A11/ferroptosis; PHGDH R54/R20, PGK1 R206, DDX3 methylation; STAT1/MHC-I suppression; nuclear MAFF/BACH1 restraint\",\n      \"pmids\": [\"38839752\", \"36995937\", \"38605214\", \"38383964\", \"38402202\", \"39042374\", \"38401121\", \"38691454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of competing localization signals (phospho/acetyl) not unified mechanistically\", \"Causal hierarchy among multiple metabolic substrates unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected PRMT1 to neurodegenerative proteostasis by showing methylation controls phase separation and aggregation of an ALS-relevant substrate.\",\n      \"evidence\": \"TDP-43 R293 in vitro methylation, LLPS and aggregation assays, p38α phospho cross-talk, ALS patient-derived motor neurons\",\n      \"pmids\": [\"39817908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic modulation of this axis in vivo untested\", \"Stoichiometry of methylation vs phosphorylation in patient tissue unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how PRMT1 selects among its very large substrate repertoire in a given cell, and how its competing localization, modification, and degradation signals are integrated into context-specific outputs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for substrate prioritization across nucleus, cytoplasm, Golgi, ER, and mitochondria\", \"Quantitative occupancy and stoichiometry of most methylation sites in vivo unknown\", \"Adaptor- vs intrinsic-specificity contributions not systematically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 6, 9, 12, 22, 34, 40, 49, 55]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 6, 9, 12, 27, 34, 39, 40, 43, 55]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [22, 25, 31, 61]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 3, 22, 31]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15, 22, 25, 41, 62, 63]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17, 41, 62]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [22, 25, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 22, 31, 36, 45]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [5, 18, 32, 38, 42, 47]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 34, 39, 53]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 13, 16, 20, 34]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [40, 42, 49, 50, 58]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [9, 27, 33]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [14, 54]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22, 31, 45, 61]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [21, 43, 62]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PRMT2\", \"TR3\", \"EGFR\", \"TBK1\", \"EZH2\", \"IGF1R\", \"FLT3\", \"GFI1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}